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HIV Transmission, Entry, and Gene Therapy
Abstract
For HIV to enter cells, the viral surface protein Envelope (Env) must sequentially bind the host protein CD4
and one of two coreceptors, either CCR5 or CXCR4. This triggers conformational changes in Env that
result in fusion of the host and viral membranes. Our understanding of this process has led to the
development of successful anti-viral drugs and provided insights into viral pathogenesis. One critical
question is whether we can further exploit our knowledge of the HIV entry process to develop an effective
therapeutic vaccine. To do this, we need to better understand HIV-1 transmission, which may reveal viral
properties that could be targeted in future vaccine efforts. In chapter two, we conduct a phenotypic
comparison of clade B transmitted/founder (T/F) and chronic HIV-1 Envs in an attempt to reveal viral
properties associated with successful transmission. We demonstrate that T/F Envs are more sensitive to
neutralization by CD4 binding site antibodies and that this correlates with antibody binding suggesting T/
F Envs have subtle but potentially important structural differences that may have implications for HIV-1
transmission and vaccine design. A second critical question is how can we provide long-term viral control
in the absence of anti-retroviral therapy. Recently, an HIV-1 infected individual was ‘cured’ after receiving a
bone marrow transplant from an uninfected donor who had a naturally occurring mutation in CCR5. This
suggests genetic disruption of the HIV coreceptors may provide clinical benefit. Previously ccr5-specific
zinc finger nucleases (R5-ZFNs) were developed to disrupt ccr5 and engineer HIV-resistant cells. ZFNs
are DNA binding proteins that specifically bind and cleave a specific 24 base pair DNA target. After
cleavage, error-prone host DNA repair pathways often introduce mutations resulting in a non-functional
gene product. Since 50% of late-stage HIV-infected people harbor virus that can use CXCR4, we developed
cxcr4-specific ZFNs (X4-ZFNs) that safely and efficiently disrupt cxcr4 conferring resistance to X4 HIV
both in vitro and in humanized mice in vivo. Genome editing with ZFNs results in HIV-resistant cells that
can be re-infused into a patients own body and hopefully confer therapeutic benefit.
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ABSTRACT

HIV TRANSMISSION, ENTRY, AND GENE THERAPY
Craig B. Wilen
Robert W. Doms

For HIV to enter cells, the viral surface protein Envelope (Env) must sequentially
bind the host protein CD4 and one of two coreceptors, either CCR5 or CXCR4. This
triggers conformational changes in Env that result in fusion of the host and viral
membranes. Our understanding of this process has led to the development of successful
anti-viral drugs and provided insights into viral pathogenesis. One critical question is
whether we can further exploit our knowledge of the HIV entry process to develop an
effective therapeutic vaccine. To do this, we need to better understand HIV-1
transmission, which may reveal viral properties that could be targeted in future vaccine
efforts. In chapter two, we conduct a phenotypic comparison of clade B
transmitted/founder (T/F) and chronic HIV-1 Envs in an attempt to reveal viral properties
associated with successful transmission. We demonstrate that T/F Envs are more
sensitive to neutralization by CD4 binding site antibodies and that this correlates with
antibody binding suggesting T/F Envs have subtle but potentially important structural
differences that may have implications for HIV-1 transmission and vaccine design. A
second critical question is how can we provide long-term viral control in the absence of
anti-retroviral therapy. Recently, an HIV-1 infected individual was ‘cured’ after receiving
a bone marrow transplant from an uninfected donor who had a naturally occurring
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mutation in CCR5. This suggests genetic disruption of the HIV coreceptors may provide
clinical benefit. Previously ccr5-specific zinc finger nucleases (R5-ZFNs) were
developed to disrupt ccr5 and engineer HIV-resistant cells. ZFNs are DNA binding
proteins that specifically bind and cleave a specific 24 base pair DNA target. After
cleavage, error-prone host DNA repair pathways often introduce mutations resulting in a
non-functional gene product. Since 50% of late-stage HIV-infected people harbor virus
that can use CXCR4, we developed cxcr4-specific ZFNs (X4-ZFNs) that safely and
efficiently disrupt cxcr4 conferring resistance to X4 HIV both in vitro and in humanized
mice in vivo. Genome editing with ZFNs results in HIV-resistant cells that can be reinfused into a patients own body and hopefully confer therapeutic benefit.
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Chapter 1
Introduction to HIV entry
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Abstract
The first step of the HIV replication cycle - binding and entry into the host cell plays a major role in determining viral tropism and the ability of HIV to degrade the
human immune system. HIV utilizes a complex series of steps to deliver its genome into
the host cell cytoplasm while simultaneously evading the host immune response. To
infect cells, the HIV protein Envelope (Env) binds to the primary cellular receptor CD4
and then to a cellular coreceptor. This sequential binding triggers fusion of the viral and
host cell membranes, initiating infection. Revealing the mechanism of HIV entry has
profound implications for viral tropism, transmission, pathogenesis, and therapeutic
intervention. Here, we provide an overview into the mechanism of HIV entry, provide
historical context to key discoveries, discuss recent advances, and speculate upon future
directions in the field.
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HIV entry fundamentals
HIV entry, the first phase of the viral replication cycle, begins with adhesion of
virus to the host cell and ends with the fusion of the cell and viral membranes with
subsequent delivery of the viral core into the cytoplasm. The intricate series of proteinprotein interactions that ultimately results in virus infection can be divided into several
phases, some of which are essential and others that may serve to modulate the efficiency
of the process. First, virions must bind to the target cell, with this being mediated either
by the viral envelope (Env) protein or host cell membrane proteins incorporated into the
virion with any one of a number of various cell attachment factors. Attachment can be
relatively non-specific, with Env interacting with negatively charged cell surface heparan
sulfate proteoglycans [1], or can result from more specific interactions between Env and
α4β7 integrin [2,3] or pattern recognition receptors such as DC-SIGN [4](reviewed in [5].
HIV attachment to the host cell via any of these factors likely brings Env into close
proximity with the viral receptor CD4 and coreceptor, increasing the efficiency of
infection [6] (Figure 1-1). However, attachment factors differ from receptors in that they
are not essential, and while they augment infection in vitro their physiologic role in vivo
remains unclear.
The second step of virus entry and the first absolutely required for infection entails
binding of Env to its primary receptor, the host protein CD4 [7,8]. Env is a heavily
glycosylated trimer of gp120 and gp41 heterodimers. The gp120 subunit is responsible
for receptor binding. The gp120 contains five relatively conserved domains (C1-5) and
five variable loops (V1-V5), named for their relative genetic heterogeneity. Each of the
variable regions is comprised of a loop structure formed by a disulfide bond at its base,
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Figure 1-1. Overview of HIV entry. To deliver the viral payload into cells, HIV Env,
comprised of gp120 and gp41 subunits (1) first attaches to the host cell, binding CD4 (2).
This causes conformational changes in Env allowing coreceptor binding, which is
mediated in part by the V3 loop of Env (3). This initiates the membrane fusion process
as the fusion peptide of gp41 inserts into the target membrane, followed by six-helix
bundle formation and complete membrane fusion (4).
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with the exception of V5. The variable loops lie predominantly at the surface of gp120
and play critical roles in immune evasion and coreceptor binding, particularly the V3
loop (reviewed in [9]. CD4 is a member of the immunoglobulin superfamily that
normally functions to enhance T cell receptor mediated signaling. Env interacts with the
CD4 binding site (CD4bs) in gp120 [10]. Env binding to CD4 causes rearrangements of
V1/V2 and subsequently V3. In addition, CD4 binding leads to formation of the bridging
sheet, a four-stranded beta-sheet comprised of two double-stranded beta sheets that are
spatially separated in the unliganded state [10,11]. The bridging sheet and repositioned
V3 loop play critical roles in the next step of virus entry, coreceptor engagement.
The third step of virus entry, coreceptor binding, is widely thought to be the trigger that
activates the membrane fusion potential of Env. HIV strains can be broadly classified
based on their coreceptor usage. Viruses that use the chemokine receptor CCR5 are
termed R5 HIV, those that use CXCR4 are termed X4 HIV, and viruses that can utilize
both coreceptors are called R5X4 HIV [12]. There is no compelling evidence that
coreceptors other than CCR5 and CXCR4 play important roles in supporting infection of
HIV-1 in vivo. With rare exception, only R5 and R5X4 viruses are transmitted between
individuals [13], likely due to multiple imperfect but overlapping host restrictions on X4
HIV transmission (reviewed in [14]). Interestingly, despite identification at earlier time
points and despite high levels of CXCR4 expression on circulating HIV target cells, X4
or even R5X4 HIV rarely predominate until late in infection [15,16,17]. In addition, X4
viruses are less common in clade C HIV and SIV infection [18,19,20,21]. Several nonmutually exclusive models may explain this. First, clade B Envs may be different in their
ability to adapt to CXCR4-tropism. Second, there may be differences in clade B host
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biology. For instance, clade B hosts may have mitigated neutralizing antibody or
cytotoxic T lymphocyte responses against X4 HIV compared to R5 HIV. Finally, clade
B hosts most often live in developed countries and may face different environmental
stresses including fewer or different chronic co-infections, which may increase target cell
CCR5 expression. Elucidating the mechanism of coreceptor switch is a critical next step
as it has implications for disease progression and therapy with HIV entry inhibitors.
A fourth step of virus entry is movement of the virus particle to the site where productive
membrane fusion occurs. A series of recent studies have shown that a number of viruses
usurp cellular transport pathways to reach specific destinations that are either needed for
infection or that make entry more efficient, and that HIV might likewise utilize the host
cell machinery to reach sites where membrane fusion can occur [22,23,24]. Some viruses
have been shown to 'surf' along the cell surface, moving from distal sites of attachment to
more proximal regions of the cell body where virus entry occurs. Retroviruses, including
HIV, have been shown to utilize this process on some cell lines [24]. In addition, HIV
may need to be internalized by the host cell's endocytic machinery in order for productive
membrane fusion to occur, as will be discussed in a later section [25].
The fifth and final step of virus entry is membrane fusion mediated by Env.
Coreceptor binding induces exposure of the hydrophobic gp41 fusion peptide, which
inserts into the host cell membrane. This tethers the viral and host membranes, allowing
the fusion peptide of each gp41 in the trimer to fold at a hinge region, bringing an Nterminal helical region (HR-N) and a C-terminal helical region (HR-C) from each gp41
subunit together to form a six-helix bundle (6HB) [26,27]. As the HR-N domain is in
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close proximity to the host cell membrane due to the fusion peptide and the HR-C
domain is in close proximity to the viral membrane due to the gp41 transmembrane
domain, formation of the 6HB is the driving force that brings the opposing membranes
into close apposition, resulting in the formation of a fusion pore (reviewed in [28].
Whether one or multiple HIV Env trimers are needed for complete membrane fusion is
not yet clear. In summary, coreceptor binding unlocks the potential energy of the gp41
fusion complex resulting in 6HB formation, opening and stabilization of the membrane
fusion pore, and subsequent delivery of the viral contents into the host cell cytoplasm.

Discovery of the HIV receptors
In 1981, several years before the discovery of HIV, Gottlieb and colleagues
reported CD4+ T cell decline in four men who presented with Pneumocystis pneumonia
and mucosal candidiasis, among other opportunistic infections [29]. Three years later it
was demonstrated that HIV preferentially infects CD4+ T cells [30], and that infection is
potently inhibited by CD4-specific antibodies (reviewed in [31]. CD4 was then shown to
coimmunprecipitate with Env [7] and CD4 expression could rescue infection in some
non-permissive cells [8]. However, CD4 transfection into mouse cells rescued binding of
virus to the cell surface but not membrane fusion and virus infection, suggesting there
were other required cofactors [8].
While the discovery of CD4 as the primary HIV receptor occurred shortly after the
onset of the epidemic, it took more than a decade to discover the first coreceptor. In
1993, CD26 was reported as the elusive HIV coreceptor [32]; however, this was later
disproved by several groups [33,34]. In 1995, Feng and colleagues conclusively
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identified CXCR4 as a major HIV coreceptor by the use of an expression cloning
strategy. A critical finding of this study was that CXCR4, then termed fusin, functioned
as a coreceptor for what had been termed T cell line tropic strains of HIV but not for
virus strains that could infect human macrophages but that failed to enter T cell lines
[35,36]. The seminal discovery of CXCR4 as a G- protein coupled receptor in
combination with the identification of the inhibitory effect of the β-chemokines CCL3
(MIP-1α), CCL4 (MIP1β), and CCL5 (RANTES) [37] on some virus isolates led to the
simultaneous and rapid discovery of CCR5 as the coreceptor for macrophage tropic virus
strains by five different groups [38,39,40,41,42].
The importance of the viral coreceptors for HIV infection in vivo was demonstrated by
the discovery of a 32 base-pair deletion in ccr5, termed ccr5Δ32, that has an allelic
frequency of approximately 10% in Caucasians [43,44,45]. The Δ32 mutation results in a
premature stop codon in the second extracellular loop of CCR5 and subsequent retention
of the mutant protein in the endoplasmic reticulum. Homozygosity for this
polymorphism results in profound resistance to HIV infection, though several Δ32
homozygotes have been infected with X4 viruses [46,47,48]. In addition, heterozygosity
confers partial protection to infection [43,45] and disease progression [45,49].
Elucidating the mechanism of HIV entry has directly translated into therapeutic benefit.
Currently, there are two FDA-approved entry inhibitors, enfuvirtide and maraviroc, while
others are in various stages of development. In 2003 enfuvirtide became the first licensed
entry inhibitor; it is a 36 residue long peptide whose sequence is based on that of the HRC in gp41. As a result, enfuvirtide behaves much like HR-C in that it binds to the HR-N
prehairpin intermediate and inhibits 6HB formation and subsequent membrane fusion
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[50,51]. While enfuvirtide is a highly specific and effective membrane fusion inhibitor
[52,53], its use has been limited since it must be injected due to its lack of oral
bioavailability. Recently, protease-resistant D-peptide fusion inhibitors have been
developed that also prevent 6HB formation, which may overcome this limitation
[54,55,56]. In addition to enfuvirtide, the CCR5 inhibitor maraviroc has been approved
for clinical use. Maraviroc is a small molecule allosteric inhibitor that binds within the
CCR5 transmembrane cavity resulting in conformational changes in the extracellular loop
domains of the chemokine receptor that interact with Env [57]. Similar CCR5 small
molecule inhibitors are in various stages of testing (reviewed in [58].

Key recent advances
Our understanding of the HIV entry process is derived largely from structural and in
vitro studies. As the field has evolved, there is now increased emphasis on placing the
now rather well understood membrane fusion reaction in a cellular context, asking where
and when virus entry takes place as well as on how virus particles are transferred between
cells. Increased structural detail continues to provide insight into the entry process and
suggests targets for small molecule inhibitors and neutralizing antibodies. Finally,
attempts to recapitulate the ccr5∆32 phenotype have been developed with some being
brought forward to early stage clinical development [59].
New structural information. A full understanding of the HIV entry process
requires detailed structural information. The structure of CD4 alone and in complex with
a gp120 core-fragment has been solved for HIV [10,60] and SIV [11]. The structure of
the post-fusion 6HB in gp41 has also been determined [26,27]. What has been lacking is
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a structure of the native Env trimer and the HIV coreceptors. However, Wu et al recently
described five independent structures of CXCR4 bound to two different small molecule
antagonists which have given insight into both the tertiary and quaternary structure of the
native protein [61] (Figure 1-2). First, both chemokines and Env have have been reported
to engage CCR5 and CXCR4 in a two-site model with the chemokine receptor Nterminus as site one and the extracellular loops (ECLs), particularly ECL2 as site two.
While the orientation of the CXCR4 N-terminal domain could not be solved due to
structural flexibility, the crystal structure provides high-resolution insight into the ECL2
binding site. Second, all five structures portray CXCR4 as a homodimer, which is
consistent with biochemical studies that have suggested CXCR4 exists as an oligomer in
the host cell membrane [62]. While the implications of CXCR4 dimerization remain
unclear for HIV infection, it may explain the dominant phenotype of a C-terminal
CXCR4 human mutation that results in WHIM syndrome that is characterized by warts,
hypogammaglobulinemia, infections, and myelokathexis (retention of neutrophils in the
bone marrow) [63]. Finally, the identified homodimer interface may represent a novel
CXCR4 or potentially CCR5 drug target, as CCR5 and CXCR4 have been reported to
heterodimerize in vivo [64,65]. Further structural studies are needed to better define the
precise interactions of Env and coreceptor and to assess the mechanisms of signaling and
heterodimerization with other chemokine receptors.
Where does virus entry occur? The entry of viruses into cells is controlled in
both time and space, with these parameters being regulated by host cell factors that serve
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Figure 1-2. Model of gp120 engagement of CD4 and CXCR4. Recent structural
studies have enhanced our understanding of the molecular interactions between gp120
(cyan) and its receptors. Here CD4 (green) and CXCR4 (purple), shown as monomers
for clarity, are shown simultaneously binding to gp120. (A) Lateral view (B) Top view.
However, the number of CD4 and coreceptor molecules required to interact with Env to
mediate productive fusion remains unknown. (C) Gp120 has two key interactions with
coreceptor. (1) The base of the V3 loop binds to the N-terminal domain of the coreceptor
while the tip of the V3 loop binds to the second extracellular loop (ECL2). While both
interactions are important, viral strains differ on their dependency of each interaction.
Structural model generated by [61].
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to unlock the membrane fusion potential of viral membrane proteins. Many viruses
require delivery by the host cell into an acidic, intracellular compartment where low pH
triggers membrane fusion-inducing conformational changes (reviewed in [66]. HIV entry
does not require low pH, instead being triggered by receptor engagement [67]. The fact
that HIV does not require low pH for cellular entry does not imply that fusion occurs at
the cell surface. In fact, no spatial information is provided by the triggering mechanism.
Despite this, it was often assumed that HIV fuses at the cell surface due to several
observations (reviewed in [68]}. First, Env expression on the cell surface can mediate
cell-to-cell fusion, indicating not only that Env is the only viral membrane protein needed
to elicit fusion but that low pH is clearly not required. Second, very early studies on HIV
entry showed that lysomotropic agents, which increase endosomal pH, do not inhibit HIV
infection [69]. Third, inhibiting endocytosis of CD4 in cell lines by mutating its
cytoplasmic domain does not affect HIV infection [70]. Together, these studies show
that HIV entry is not pH dependent, but provide no definitive information as to whether
fusion occurs at the cell surface or from within endocytic vesicles, albeit in a pHindependent fashion.
The question of where HIV-membrane fusion occurs has recently been re-examined
[25]. By combining lipid and content mixing assays with single virion fluorescent
imaging, Miyauchi et al tracked the location of virus membrane fusion in HeLa cells
over-expressing CD4, CCR5, and CXCR4. They found that while lipid mixing can occur
at the cell surface, content mixing only occurred in intracellular perinuclear
compartments, and thus concluded that complete fusion requires endocytosis. Whether
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this is always the case remains to be determined as the genetic variability of HIV and the
diverse cell types it can infect make generalization difficult.
An interesting question is whether the site of entry matters. With regards to the use of
entry inhibitors, probably not: both coreceptor antagonists and fusion inhibitors block
virus infection in vitro and in vivo, and neutralizing antibodies clearly function as well.
However, the site of entry is more likely to have an impact on the likelihood of a
productive infection actually occurring. For instance, after cellular attachment, HIV can
actively ‘surf’ along the cellular membrane from filopodia or microvilli to the cell body.
This actin-dependent process requires receptor engagement and serves to enhance
infection efficiency. Surfing towards the cell body may have several favorable
consequences for the virus. First, it may facilitate endocytic HIV uptake. Second, it may
bring the virus to a membrane region that has higher levels of coreceptor or important
downstream signaling molecules [71]. Third, it may allow the fusion event to occur
closer to the nucleus, which is the ultimate target of HIV. Thus, the site of initial HIV
attachment is likely random; however, HIV hijacks the cellular machinery to traverse the
cell membrane to a more favorable site of entry, be it at the plasma membrane or
endosome, which ultimately serves to augment infection efficiency [24].
Cell-cell transfer and the virological synapse. In vitro, the rate-limiting step of
virus infection is attachment to the host cell. In vivo, newly produced virions may well
encounter an immediately adjoining, uninfected cell. In some cases, transfer of virus
from one cell to another is a specialized process, as in the case of dendritic cells (DCs),
which are professional antigen presenting cells that scavenge the periphery, sampling
antigen. They are commonly found in the mucosa, and thus may be encountered by HIV
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during transmission. Upon antigen binding, DCs migrate to the lymph nodes, process,
and present the antigen to T cells to trigger an adaptive immune response. DCs are
relatively resistant to productive HIV infection due to a combination of low CD4 and
coreceptor expression, host restriction factors, post-integration HIV transcription blocks,
and other unknown factors [72]. However, they express a diverse range of attachment
factors that facilitate the internalization and processing of pathogens prior to antigen
presentation. HIV, along with other viruses [73,74], can take advantage of this pathway
to augment infection efficiency and dissemination (reviewed in [75]; Figure 1-3).
Cameron et al. first demonstrated that DCs could catalyze HIV infection of co-cultured
CD4+ T cells without themselves getting productively infected [76]. Each DC can bind
up to several hundred virions [71] most likely via a C-type lectin such as DC-SIGN
[4,77]. After binding, the virions are endocytosed into a trypsin-resistant compartment
[4], and then upon DC binding to a T cell, internalized virus migrates to the DC:T cell
interface [71] where it encounters the T cell membrane forming the infectious synapse,
analogous to the immunologic synapse that forms upon MHC-T cell receptor binding
(reviewed in [78]). In addition to efficiently concentrating and presenting HIV at the site
of T cell contact, the infectious synapse is characterized by recruitment of CD4, CCR5,
and CXCR4.
Recent advances in electron microscopy have enabled 3D-structural studies of the
infectious synapse that have shed light on this mechanism [79]. DCs produce
membranous protrusions that engulf the surrounding extracellular environment, trapping
virions in a surface-accessible but protected compartment. It remains unclear as to
whether this occurs before or after virion binding and whether it is Env-induced. When
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CD4+ T cells contact DCs, they extend filopodia, enriched for CD4 and coreceptor, into
the invaginated DC compartments that contain bound virions (Figure 1-3). Together, the
efficient binding of HIV, relocalization to the point of CD4+ T cell contact, and the
recruitment of the requisite HIV entry receptors promote HIV infection at the infectious
synapse [71,80].
A novel attachment factor: α4β7 integrin. While cell-to-cell transmission of HIV
augments infection efficiency, the mechanism of virological synapse formation remains
unclear. α4β7 integrin has been reported to bind gp120, induce activation of LFA-1
(αLβ2 integrin), which contributes to formation of the immunologic synapse (reviewed in
[81]), and subsequently augment infection efficiency in vitro [2,3].
α4β7 is a heterodimeric protein comprised of an α4 and β7 subunit that when expressed
on CD4+ T cells facilitates homing to the gut and other mucosal tissues. Its activation
and expression are upregulated by retinoic acid in vitro, which may also be locally
secreted by mucosal DCs in vivo. The discovery of α4β7 as an attachment factor is of
particular interest since HIV disrupts the integrity of the mucosal barrier and
preferentially depletes gut CD4+ T cells, which are more activated and express higher
levels of CCR5 than peripheral CD4+ T cells. α4β7 is thought to bind an LDV tripeptide
motif on the second variable loop (V2) of gp120, with this resulting in LFA-1 activation.
In addition, α4β7 colocalizes with CD4 and CCR5 at the virological synapse, which may
further enhance infection. Blockade of α4β7 with monoclonal antibodies or a peptide
delays replication of HIV in vitro further supporting its role in HIV infection [3]. Future
work is needed to assess whether there are protective effects of inhibiting HIV-α4β7
interactions in vivo and to validate this novel attachment factor as a therapeutic target.

15

Figure 1-3. Model of DC-mediated trans-infection of CD4+ T cells. (A) DCs capture
and concentrate virions in trypsin-resistant surface accessible compartments. (B) CD4+
T cells, containing membrane protrusions, bind DCs (C) The CD4+ T cell protrusions
invade the virus-containing compartments and efficiently bind HIV. (D) Virus then
migrates towards the cell body to initiate infection. Figure reproduced with permission
[79].
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Inhibitors of HIV entry
While studying HIV entry has informed us about basic principles of virology and
cell biology, the overarching goal should be to develop novel and effective therapeutics
to limit the morbidity and mortality of the HIV/AIDS pandemic. Currently, two entry
inhibitors, the CCR5 inhibitor maraviroc and the fusion inhibitor enfuvirtide, are FDAapproved for the treatment of HIV infection. A number of other compounds that have
targeted nearly every step of the entry pathway have also been tested in the clinic. For
purposes of this discussion on therapeutics, HIV entry will be divided into three
components: (1) attachment and CD4 binding, (2) coreceptor binding, and (3) membrane
fusion.
Attachment and CD4 binding inhibitors. Attachment and CD4 binding inhibitors
include relatively non-specific anionic polymers, CD4 binding site inhibitors, soluble
CD4 mimetics, and CD4 down-modulators. Anionic polymers, which act by preventing
the favorable electrostatic interactions between the positively charged Env and negatively
charged cell surface, have been predominantly studied for use in vaginal microbicides.
PRO2000, a naphthalene sulfonate polymer, inhibits soluble gp120 and CD4 binding in
vitro [82]. However, in a phase III clinical microbicide trial, PRO2000 demonstrated no
efficacy [83]. Other anionic polymers including cellulose sulfate and Carraguard, derived
from seaweed, demonstrated no efficacy and cellulose sulfate may have actually
increased the risk of HIV transmission [84,85,86].
Another approach involves targeting the CD4 binding site on gp120. Several small
molecules that bind to gp120, such as BMS-378806 and BMS-488043, have anti-viral
activity in vitro and prevent CD4-gp120 binding [87,88]. However, for at least BMS-
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378806, HIV quickly adapts resistance limiting its therapeutic potential [88].
Furthermore, soluble CD4 (sCD4) demonstrated anti-HIV activity in vitro, but early stage
clinical trials were unable to demonstrate antiviral activity, most likely due to insufficient
circulating concentrations of sCD4 [89]. An additional class of compounds inhibits EnvCD4 interactions by down-regulating CD4. These drugs, derivatives of
cyclotrizadisulfonamide (CADA) [90] reduce CD4 expression by an unknown
mechanism. However, they do not alter CD4 mRNA levels suggesting they exert their
function in a post-transcriptional manner [91].
Coreceptor binding inhibitors. Discovery of the ccr5Δ32 mutation demonstrated
that CCR5 is not essential for normal human growth and development, suggesting that it
could be safely targeted by small molecule inhibitors [43,44,45]. Several small molecule
CCR5 antagonists have been developed and shown to have antiviral activity in vivo,
including maraviroc, which received FDA approval in 2007 for use in treating HIVinfected individuals. Most small molecule CCR5 inhibitors, including maraviroc,
function by binding to a hydrophobic pocket within the transmembrane domains of the
protein - a region of the receptor not thought to directly interact with the viral Env protein
[58,92,93]. As a result, CCR5 antagonists likely function by an allosteric mechanism,
inducing conformational changes in the ECL domains of the receptor that subsequently
prevent Env binding. Viral resistance to such compounds occurs by one of two
pathways. In vivo, it appears that the most common resistance pathway is outgrowth of
CXCR4-using viruses, even when present below the limit of detection in standard assays
at the initiation of therapy. A second, less common pathway results from mutations in
Env that enable it to utilize the drug-bound conformation of the receptor [94]. In at least
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some cases, it appears that enhanced utilization of the CCR5 N-terminal domain is
associated with this phenotype. In addition to traditional small molecule inhibitors,
CCR5 blocking antibodies are being explored for therapeutic purposes. One such
antibody, PRO140, blocks HIV utilization of CCR5 while preserving CCR5 ligand
function. PRO140 is currently in phase II clinical trials [58,95].
Unlike for CCR5, inhibiting CXCR4 has been met with limited success primarily due to
the concerns of systemic toxicity. Several CXCR4 inhibitors advanced to early stage
clinical trials but none are currently ongoing for the treatment of HIV. One CXCR4
inhibitor, plerixafor, was recently FDA approved to mobilize hematopoetic stem cells to
the peripheral blood for harvesting prior to bone marrow transplantation [96].
Fusion inhibitors. Membrane fusion is the net result of Env-receptor interactions,
and is the target of the first entry inhibitor ever approved, enfuvirtide. Enfuvirtide,
previously known as T20, is a 36 amino acid mimetic of the HR-C domain. The peptide
binds the central coiled coils comprised of three HR-N molecules and inhibits 6HB
formation, thus preventing fusion [50,51]. Despite the in vivo efficacy of enfuvirtide,
resistance mutations in a ten amino acid region of HR-N that prevents enfuvirtide binding
have been well documented [97]. Importantly though, resistance to enfuvirtide does not
confer cross-resistance to other classes of entry inhibitors [98]. Novel fusion peptidebased inhibitors have been designed to combat enfuvirtide resistant viruses and some of
these molecules have synergistic effects with enfuvirtide [99,100,101].
While these peptide-based fusion inhibitors exhibit efficacy, they are limited by the
fact that are not orally bioavailable and therefore must be injected, a significant hindrance
in maintaining patient adherence. One potential solution is the development of orally
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bioavailable small molecules that recapitulate enfuvirtide’s mechanism of action by
blocking the hydrophobic “knob-into-hole” interactions. The knobs are hydrophobic HRC residues, specifically tryptophans and isoleucines, that pack into large hydrophobic
holes present in the HR-N central coil [26]. D-peptide inhibitors of gp120 represent one
such exciting new class of compounds. They have potent in vitro activity and are not
degraded by intestinal proteases and thus have the potential to be orally bioavailable [56].
Critical remaining questions
Work on the mechanisms of HIV entry has led to the discovery of human mutations
affecting HIV susceptibility and disease progression as well as the development of new
antiviral agents, such as enfuvirtide and maraviroc. In addition to the continued
development of entry inhibitors, a critical future challenge is translating our molecular
understanding of HIV entry into therapeutically useful information. Two critically
important goals are the development of a preventative HIV-1 vaccine and a treatment that
can functionally “cure” HIV-1 infected individuals. In this thesis, we attempt to make
progress towards both of these goals.
HIV transmission is a relatively inefficient process characterized by infection in
roughly 1 per 1,000 coital acts [102,103]. In approximately 80% of cases, transmission is
mediated by a single virus, called the transmitted/founder (T/F) virus, despite significant
viral diversity in the donor inoculum [13]. This results in a profound genetic bottleneck
[13,104,105,106,107,108,109,110]. Questions of critical importance are what causes this
bottleneck, what viral properties facilitate transmission, and can this knowledge be
exploited for therapeutic gain. In chapter two, we assess the phenotypic properties of
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transmitted/founder Env glycoproteins in an attempt to to better understand HIV
transmission and pathogenesis and find HIV-1’s Achilles’ heal to aid in vaccine design.
In chapter three, we discuss a novel therapeutic strategy to engineer HIV-resistant
CD4+ T cells with a long-term goal of achieving a functional “cure,” that is, virologic
control in the absence of long-term anti-retroviral therapy (ART). Despite the success of
ART, there are significant toxicities associated with its chronic use, and thus improved
treatment is needed. One such approach involves genetically disrupting the HIV
coreeceptors, ccr5 and cxcr4, with gene-specific zinc-finger nucleases (ZFNs). An
individual’s own cells can be removed, genetically modified ex vivo, and then reinfused
creating a population of cells resistant to HIV infection. These cells should have a
survival advantage in vivo and may serve to maintain a functional immune system and
prevent progression to AIDS.
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Abstract
Sexual transmission of human immunodeficiency virus type 1 (HIV-1) across
mucosal barriers is responsible for the vast majority of new infections. This relatively
inefficient process results in the transmission of a single transmitted/founder (T/F) virus - from a diverse viral swarm in the donor -- in approximately 80% of cases. Here we
compared the biological activity of 24 clade B T/F envelopes (Envs) with that of 17
chronic controls to determine whether the genetic bottleneck that occurs during
transmission is linked to a particular Env phenotype. To maximize the likelihood of an
intact mucosal barrier in the recipients and to enhance the sensitivity of detecting
phenotypic differences, only T/F Envs from individuals infected with a single T/F variant
were selected. Using pseudotyping to assess Env function in single round infectivity
assays, we compared coreceptor tropism, CCR5 utilization efficiency, primary CD4+ T
cell subset tropism, dendritic cell trans-infection, fusion kinetics, and neutralization
sensitivity. T/F and chronic Envs were phenotypically equivalent in most assays;
however, T/F Envs were modestly more sensitive to CD4 binding site antibodies b12 and
VRC01, as well as pooled human HIV Ig. This finding was independently validated with
a panel of 14 additional chronic HIV-1 Envs controls. Moreover, the enhanced
neutralization sensitivity was associated with more efficient binding of b12 and VRC01
to T/F Env trimers. These data suggest that there are subtle but significant structural
differences between T/F and chronic clade B Envs that may have implications for HIV-1
transmission and the design of effective vaccines.
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Introduction
Sexual transmission of HIV-1 across mucosal barriers is a relatively inefficient
process and is most often due to the transmission of a single transmitted/founder (T/F)
virus from the swarm of viral variants present in the donor, resulting in a profound
genetic bottleneck [1,2,3,4,5,6,7,8]. As discussed in chapter one, a question of central
importance is whether T/F viruses have particular phenotypic properties, which favor
their transmission. If so, viruses with these properties should logically be targets of
vaccination and microbicide efforts. The viral envelope (Env) protein is a likely
candidate for transmission-related signatures. For example, viruses expressing Envs that
utilize the CCR5 coreceptor (R5-tropic) are transmitted far more frequently than those
expressing Envs that utilize CXCR4 (X4-tropic) [1,6,9,10]. Variations in Env have also
been linked to differences in the utilization of CD4 and coreceptor, the rate and efficiency
of membrane fusion, as well as binding to C-type lectins such as DC-SIGN that are
expressed on dendritic cells (DCs) and can function as virus attachment factors
[11,12,13,14].
Studies to characterize the properties of transmitted HIV-1 strains face several
challenges. First, it is difficult to identify individuals during the acute phase of HIV-1
infection, particularly before the onset of immune responses (that is, at early Fiebig
stages [15]), thus limiting sample sizes. Second, individual viruses cloned from the
peripheral blood or plasma of acutely infected individuals within weeks of transmission
may have already evolved away from the actual T/F virus and may thus have acquired
phenotypic changes [16]. Third, in the absence of extensive sampling of the early viral
quasispecies by single genome amplification (SGA), it is impossible to know if one or
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more virus strains established the clinical infection, making it difficult to assess the
integrity of the mucosal barrier [1]. Infection with multiple T/F viruses may reflect a
different mechanism of transmission, with these T/F Envs likely facing different or
reduced transmission selection pressure [17,18]. Nonetheless, small numbers of Envs
cloned from acutely infected individuals have been obtained and compared to Envs
cloned from corresponding donors or from other chronically infected individuals.
Derdeyn et al. examined clade C Envs from eight heterosexual transmission pairs and
concluded that transmitted Envs have fewer putative N-linked glycosylation sites
(PNGs), more compact variable loops, and enhanced neutralization sensitivity to donor
plasma [2], although subsequent phenotypic studies of a subset of viruses bearing these
Envs did not reveal functional differences [19,20]. Analysis of clade A and D
transmission pairs also identified shorter recipient Envs with a lower V3 charge, although
no differences in the number of PNGs were noted [21]. For clade B Envs, initial studies
suggested that transmission was independent of variable loop length and PNGs
[22,23,24]; however, more recent comparisons of thousands of clade B T/F and chronic
env sequences confirmed significantly fewer total PNGs and a trend towards fewer in the
V1/V2 loops of transmitted Envs (Gnanakaran et al, submitted). Finally, several studies
have investigated neutralization sensitivities of acute or T/F Envs compared to chronic
control Envs, but reported conflicting results [1,23,25,26]. These discrepancies may have
resulted from differences in sample size, demographics of acutely infected individuals
and chronic controls, cloning strategy, and whether the Envs under investigation
represented true T/F viruses.
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The use of SGA of plasma viral RNA during the earliest stages of infection has
allowed the inference of the nucleotide sequence of T/F viruses from an increasingly
large number of individuals [1,27,28,29]. Recent analyses of a large number of clade B
T/F Env sequences led to the identification of transmission signatures in the CCR5
binding site, certain PNGs, and sites in the signal peptide and gp41 cytoplasmic domain
that could affect Env processing and localization (Gnanakaran et al, submitted). These
results suggested that T/F Envs might differ in some phenotypic properties from chronic
Envs. To examine this, we conducted a comprehensive phenotypic analysis of T/F and
chronic clade B HIV-1 Envs in the context of viral pseudotypes. Specifically, we
assessed coreceptor tropism, CCR5 utilization efficiency, CD4+ T cell subset tropism,
DC-mediated trans-infection efficiency of T cells, and membrane fusion kinetics. In
addition, we examined the sensitivity T/F and chronic Envs to neutralization by purified
immunoglobulin from infected patients (HIV Ig) and a panel of broadly neutralizing
monoclonal antibodies (MAbs) and assessed the binding efficiencies of these MAbs to
trimeric Env on the cell surface. Our results failed to identify a major transmission
phenotype, but uncovered subtle functional differences between T/F and chronic Envs
that may be of biological significance.
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Materials and Methods
Pseudovirus production. Pseudotyped virus was produced by calcium
phosphate co-transfection of 6 µg of pcDNA3.1+ containing env with 10 µg of HIV-1
core (pNL43-ΔEnv-vpr+-luc+ or pNL43- ΔEnv -vpr+-eGFP) into 293T17 cells. Virus
was harvested 72 hours post-transfection, filtered through a 0.45 µm filter, aliquoted, and
stored at -80°C. For the primary CD4+ T cell infection, pseudovius was concentrated by
ultracentrifugation through a 20% sucrose cushion. Pelleted pseudovirus was then
resuspended in PBS. All luciferase-encoding pseudoviral stocks were serial diluted and
used to infect NP2 cells to define the linear range of the assay. A viral dilution was
chosen in the middle of the five-fold linear range of the assay to maximize sensitivity.
Env cloning and sequence analysis. The derivation of most T/F Env clones used
in this study has been described [1]. THRO.F4.2026, SUMAd5.B2.1713, 901009.A1.4924, and PRB959-02.A7.4345 were cloned from SGA amplicons known to
contain the nucleotide sequence of the corresponding T/F env sequence into pcDNA3.1
according to manufacturer’s instructions (Invitrogen). The AD17.1 env gene was
subcloned from a full-length infectious molecular T/F clone described elsewhere [17].
Chronic Envs HEMA.A4.2125 and HEMA.A23.2143 were also cloned in pcDNA3.1;
briefly, viral RNA was extracted from plasma of chronically infected patients and
amplified using SGA methods. Individual env genes were then either cloned at random,
or selected, to maximize within-patient env sequence diversity. Env clones were
sequenced to confirm that they did not contain Taq polymerase errors, but represented
env genes of viruses circulating in the patient. The nucleotide sequences of all T/F and
chronic Envs have previously been reported (Gnanakaran et al, submitted). PNGs were
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determined with N-glycosite (hiv.lanl.org) [30]. To assess lengths of the V1/2, V3, V4,
V5, and V1-4 regions, sequences were aligned to HXB2, then boundaries were identified
for each region and non-gap residues were counted.
Coreceptor tropism testing and cell line infections. NP2 cells stably expressing
CD4 and either CCR5 (NP2/CD4/CCR5) or CXCR4 (NP2/CD4/CXCR4) were infected
with HIV-1 pseudoviruses expressing luciferase by spinoculating in 96-well plates at 450
g for 90 minutes at 25°C. Cells were lysed with Brite-Glo (Promega) 72 hours postinfection and analyzed on a Luminoskan Ascent luminometer. Coreceptor tropism was
arbitrarily defined by mean relative light units (RLUs) greater than 1 (approximately 100fold over background). To assess sensitivity to coreceptor inhibitors, NP2/CD4/CCR5 or
NP2/CD4/CXCR4 cells were pre-incubated for 30 minutes with saturating concentrations
of the CCR5 inhibitor maraviroc (1 µM), the CXCR4 inhibitor AMD3100 (2 µM), or the
fusion inhibitor enfuvirtide (10 µ/ml) prior to infection. To assess sensitivity to broadly
neutralizing MAbs, viral pseudotypes were pre-incubated with 10 µg/ml of antibody for
30 minutes at 37°C. Virus and antibody mixes were then used to infect NP2/CD4/CCR5
or NP2/CD4/CXCR4 cells. All NP2 cell line infections were done in at least triplicate in
at least three independent experiments using R5-tropic JRFL as a positive control and
Env-deficient pseudotypes as a negative control.
The following reagents were obtained through the NIH AIDS Research and
Reference Reagent Program, Division of AIDS, NIAID, NIH: pNL4-3-deltaE-eGFP
(Cat# 11100) from Drs. Haili Zhang, Yan Zhou, and Robert Siliciano [31], bicyclam JM2987 (hydrobromide salt of AMD-3100; Cat# 8128) [32,33,34], maraviroc (Cat #11580)
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[35,36,37], and HIV-1 gp120 MAb IgG1 b12 (Cat# 2640) from Dr. Dennis Burton and
Carlos Barbas [38,39,40,41].
Primary human CD4+ T cell tropism assay. Primary human CD4+ T cells,
purified by negative selection, were obtained from the University of Pennsylvania’s
Human Immunology Core. 2x106 cells per virus were stimulated with plate-bound antiCD3 (clone OKT3) (eBiosciences) and anti-CD28 (clone 28.2, BD biosciences) and 20
units (U)/ml recombinant IL-2 in RPMI containing 10% FBS. Three days poststimulation cells were transferred to 96-well V-bottom plates prior to infection. Five
µl/well of concentrated HIV-GFP was used to infect cells in triplicate. Plates were then
spinoculated at 1200 g for 2 hrs. Cells were then transferred to new 24-well plates and
new media containing 20 U/ml IL-2 was added. Three days post-infection, cells were
stained for flow cytometry.
Determination of alternative coreceptor use. Primary human CD4+ T cells
from two different ccr5Δ32 homozygous donors were obtained and purified as previously
described. Prior to infection, cells were pre-incubated with 50 µM AMD3100 for 30 min.
Cells were infected as previously described. Two hours after spinfection, enfuvirtide (1
µg/ml final concentration) was added to all samples to prevent additional fusion prior to
transferring cells to a 24-well plate for further incubation. Samples were stained and
analyzed as previously described.
Flow cytometry. 1-2x106 cells were stained per tube for flow cytometry. All
incubations were done at RT and in Facs Wash Buffer (PBS, 2.5% FBS, 2mM EDTA),
and all antibodies were from BD Biosciences, unless otherwise noted. To stain CD4+ T
cells, cells were first washed in PBS. Then, live/dead Aqua (Invitrogen) was added and
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incubated for 10 min. Next, anti-CCR7 IgM in Facs Wash Buffer was added and
incubated for 30 min. Cells were then washed in Facs Wash Buffer before staining with
anti-CD3 Qdot 655 (Invitrogen), anti-CD4 Alexa Fluor 700, anti-CD45RO PE-Texas Red
(Beckman Coulter), and anti-IgM PE (Invitrogen) for 30 min. Cells were then washed in
Facs Wash Buffer and resuspended in 1% PFA. Samples were run on a LSRII (BD) and
analyzed with FlowJo 8.8.6 (Treestar). Cells were gated as follows: singlets (FSC-A by
FSC-H), then live cells (SSC-A by live/dead), then lymphocytes (SSC-A by FSC-A),
then CD3+ cells (SSC-A by CD3), then by memory markers (CCR7 by CD45RO).
DC trans-infection assay. To differentiate DCs, freshly isolated monocytes from
the University of Pennsylvania’s Human Immunology core were treated with 50 ng/ml
GM-CSF (R&D systems) and 100 ng/ml IL-4 (R&D systems) in AIM V serum free
media (Invitrogen). New media containing GM-CSF and IL-4 was added on day 3. Six
days post-stimulation DCs were washed and plated at 3x104 cells per well in a V-bottom
96 well plate. 3x104 CD4+ T cells alone, three days post-stimulation with plate-bound
anti-CD3/anti-CD28 were used as a negative control. Viral stocks were first titered by
RLUs on NP2/CD4/CCR5 or CXCR4 cells. Virus sufficient to generate 80 RLUs was
added to DCs or a CD4+ T cell control and allowed to bind for two hours at 37°C. Cells
were washed three times with fresh media to remove cell-free virus. Then, 3x105
stimulated heterologous CD4+ T cells were added to each well containing 3x104 HIVbound DCs or CD4+ T cells. As an additional control, and equal amount of virus was
added to 3x105 stimulated CD4+ T cells to ensure there was no differential infection of
CD4+ T cells. For CD4+ T cell luciferase infection, cells were spinoculated at 450 g for
90 minutes and then incubated without washing off virus. Cells were then transferred to
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a flat bottom 96-well plate for three days prior to take down with Brite Glo. Each
condition was done in triplicate and each viral pseudotype was used in at least three
independent experiments with cells from different healthy donors.
Enfuvirtide time-of-addition assay. To assess entry kinetics of T/F and chronic
Envs, NL43vpr+luc+ pseudotypes were chilled to 4°C and added to NP2/CD4/CCR5 (or
NP2/CD4/CXCR4 for the one X4-tropic Env) cells on metal blocks embedded in ice
covered by a moist towel. Cells were then spinoculated at 1300 rpm for 90 minutes at
4°C to enhance viral binding. Immediately post-spinoculation, cold supernatant was
aspirated off and all wells were flooded with 270 µl of pre-warmed 37°C media and
transferred to a 37°C incubator. 30 µl of 10 µg/ml enfuvirtide (final concentration of
1µg/ml) was then added at 0, 5, 10, 20, 40, 80, or 160 minutes post-warming. A no drug
control was also included to normalize percent infection. Cells were then incubated for
72 hours and assessed for RLUs. At least three wells per virus per time point were
included in each experiment, and all Envs were examined in at least three independent
experiments. Data was analyzed with Prism 4.0 (GraphPad Software, Inc.) by fitting a
best-fit sigmoidal line to each independent experiment prior to averaging the Hill slopes
and time to half-max fusion.
Neutralization sensitivity. Neutralization assays were performed using both
NP2 and TZMbl cells in two independent laboratories. To assess sensitivity to MAbs
b12, VRC01, PG9, and PG16, viral pseudotypes were pre-incubated with 10 µg/ml of
antibody for one hour prior to infection of NP2 cells. To assess sensitivity to HIV Ig,
pseudotypes were pre-incubated with two-fold serial dilutions of clade B HIV Ig from
1500-23 µg/ml. This mix was then added to NP2 cells and spinoculated as described

45

previously. For MAbs, neutralization was assessed by determining the maximum percent
inhibition (MPI) compared to a no antibody control. Clade B HIV Ig (lot 12 100158) was
obtained from the AIDS Repository.
Neutralization sensitivity was assessed on TZMbl cells as previously described
[42,43]. Briefly, 8 x 103 TZMbl cells were plated overnight. Five-fold dilutions of MAbs
(b12, VRC01, PG9, PG16, and clade B HIV Ig) were incubated in the presence of 40
µg/ml DEAE-Dextran and 2000 infectious units (as measured on TZMbl cells) of
pseudovirius for one hour at 37°C. After media was removed from TZMbl cells, the
virus/MAb dilutions were added to the cells and incubated for 48 hours before being
analyzed for luciferase expression (Promega). The highest concentration tested for b12,
VRC01, PG19 and P16 was 10 µg/ml. The highest concentraion of clade B HIV Ig was
1500 µg/ml. Samples were tested in duplicate with all experiments repeated at least two
times. IC50 values were calculated as described previously [43].
Cell-Based Enzyme-Linked Immunosorbent Assay (CELISA). The binding of
MAbs to HIV-1 Env trimers expressed on cells was measured using a cell-based ELISA
system, as previously described [44]. Briefly, COS-1 cells were seeded in 96-well plates
(1.8 × 104 cells/well) and transfected the next day with 0.1 µg of a plasmid expressing
Env and 0.02 µg of a Rev-expressing plasmid per well using Effectene transfection
reagent. Three days later, cells were incubated with the indicated MAb suspended in
blocking buffer (35 mg/ml BSA, 10 mg/ml non-fat dry milk, 1.8 mM CaCl2, 1 mM
MgCl2, 25 mM Tris, pH 7.5 and 140 mM NaCl) for one hour at room temperature. Cells
were then washed four times with blocking buffer and four times with washing buffer
(140 mM NaCl, 1.8 mM CaCl2, 1 mM MgCl2 and 20 mM Tris, pH 7.5). A horseradish
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peroxidase-conjugated antibody specific for the Fc region of human IgG was then
incubated with the samples for 45 minutes at room temperature. Cells were washed five
times with blocking buffer and five times with washing buffer. HRP enzyme activity was
determined after the addition of 33 µl per well of a 1:1 mix of Western Lightning
oxidizing and luminol reagents (Perkin Elmer Life Sciences) supplemented with 150 mM
NaCl. Light emission was measured with a Mithras LB 940 luminometer (Berthold
Technologies). To correct for the level of cell surface expression of each envelope
glycoprotein, binding of the antibodies is expressed as percent binding of the CD4-Ig
probe at saturating concentrations (5 µg/ml). We decided a priori to exclude all envelope
glycoproteins that bound CD4-Ig at less than 20% of the binding measured for the
SC05.8H2.3243 control isolate. Five of the 57 Envs were thus not analyzed, including
three T/F and two chronic Envs. Measurements of antibody binding and neutralization
were performed under code to prevent potential bias.
Statistical analyses. T/F and chronic Envs were compared with Mann-Whitney
tests and correlations were assessed by Spearman tests. P-values less than 0.05 were
considered significant. Data was analyzed with Prism 4.0 software.
Ethics Statement. All human cells used in this study were from normal healthy
donors who provided written informed consent after approval by the University of
Pennsylvania’s institutional review board.
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Results
Panels of T/F and chronic Envs. To determine if there are functional differences
between T/F Envs and those that predominate during chronic infection, we assembled a
panel of 24 clade B T/F Envs previously inferred and cloned from plasma viral RNA of
24 individuals with acute HIV-1 infection as defined by the Fiebig staging system, in
which patients are classified from Stage I (viral RNA positive, antibody and antigen
negative) to Stage VI (ELISA and western blot positive with multiple bands) [1,17,45]
(Table 2-1). Twelve individuals were sampled during Fiebig stage II, five during Fiebig
stage III, two during in Fiebig stage IV, and five during Fiebig stage V. Acutely infected
individuals were predominantly males (22 of 24) from the southeastern United States (18
of 24) with a variety of sexual risk factors, all denying intravenous drug use (IDU). All
T/F Envs were inferred from SGA-derived sequences, which are devoid of PCR-induced
errors and cloning bias [1]. Env clones identical to this inferred T/F sequence were then
chosen for phenotypic analysis. Importantly, all T/F Envs were selected from subjects
with single variant transmissions. This was done to increase the likelihood that the
viruses encoding these Envs were transmitted across an intact mucosal barrier, thereby
maximizing our chances of observing properties required for this process [17,18].
To generate chronic clade B control Envs, we used SGA to amplify env genes
from plasma viral RNA of two groups of anti-retroviral therapy naïve individuals. The
first group consisted of 11 individuals sampled 14-83 months post-infection (mean 42
months). A test set of 17 Env clones was derived from this group consisting
predominantly of males (8 of 11) from the southeastern United States (10 of 11) all
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denying IDU (Table 2-1). An additional 14 clade B control Envs were SGA amplified
and cloned from six chronically infected individuals residing in the northwestern United
States. This second group of chronic Envs served as a validation set to confirm
differences in neutralization sensitivity observed with the first test set. A phylogenetic
tree of the 31 chronic Envs is depicted in Figure 2-1 along with the 24 T/F Envs. None of
the Envs were from epidemiologically linked infections.
Previous studies noticed fewer PNGs in the gp120 region of T/F compared to
chronic Envs [46] (Gnanakaran et al, submitted). To determine whether our selected
subset of T/F and chronic Envs differed from this much larger group, we compared
variable loop length as well as the number and distribution of putative PNGs. There were
no differences in V1/2, V3, V4, V1-4 lengths between T/F and chronic clade B Envs.
Further, the median gp120 PNGs in T/F Envs was 26.0 compared to 27.0 for the chronic
controls (p=0.16) and 26.0 for clade B Envs in general [31]. Thus, the panel of T/F Envs
selected for our functional analyses exhibited no statistically significant differences in
patient demographics, virus phylogeny, variable loop length, or PNGs relative to the
panel of chronic Envs we assembled or to clade B Envs in general.
Determination of coreceptor tropism. R5-tropic viruses represent the vast
majority of transmitted viruses, with dual (R5X4)-tropic viruses being transmitted less
frequently [1,6,9,10]. On rare occasions, X4-tropic viruses can be transmitted [47,48,49].
To determine the coreceptor usage in our panel, we characterized the CCR5 and CXCR4
utilization of the 24 T/F and 17 chronic Envs by producing viral pseudotypes and using
these to infect NP2 cell lines expressing CD4 and either CCR5 (NP2/CD4/CCR5) or
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Figure 2-1. Phylogenetic relationships of T/F and chronic Envs selected for
phenotypic analyses. The tree was constructed from Env amino acid sequences of T/F
(red), original chronic (blue), and Washington state chronic (green) control viruses
(subtype B reference sequences from the database are shown in black). All sequences
were derived by SGA methods; Env sequences from the same individuals form discrete
subclusters. A bracket indicates epidemiologically linked infections from Trinidad and
Tobago [50]. The tree was inferred using maximum likelihood methods [51]; Numbers
on nodes indicate posterior probabilities (only values above 0.95 are shown). The scale
bar represents 0.05 amino acid substitutions per site.
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CXCR4 (NP2/CD4/CXCR4), as well as primary human CD4+ T cells. NP2 cells were
selected because they provide a 5-6 log linear range of infection, approximately 2-3 logs
greater than that of the TZMbl assay. We found that of the 24 T/F Envs, 21 were R5tropic and three were R5X4-tropic, while of the 17 chronic Envs, 15 were R5-tropic, one
was R5X4-tropic, and one was X4-tropic (Table 1). This is consistent with previous
results with the exception of T/F Envs 1058-11.B11.1550 and CH77.SA2.6559, which
were R5X4-tropic on NP2 cells and R5-tropic on TZMbl cells [1] (Gnanakaran et al,
submitted). This discrepancy is likely due to differences in CXCR4 expression, as the
NP2 cells used stably express high levels of CXCR4 compared to the HeLa-derived
TZMbl cells, which express lower endogenous CXCR4 levels. All four R5X4-tropic
Envs utilized CCR5 and CXCR4 with approximately equivalent efficiency as assessed by
a less than two-fold difference in RLUs between the NP2/CD4/CCR5 and
NP2/CD4/CXCR4 cells. To assess coreceptor use on human CD4+ T cells, we infected
ccr5Δ32 or ccr5wt CD4+ T cells in the presence or absence of saturating concentrations
of the CXCR4 inhibitor AMD3100. The results paralleled those obtained with the NP2
cell lines. R5-tropic Envs mediated infection of ccr5wt but not ccr5∆32 CD4+ T cells,
while R5X4 Envs mediated infection of both cell types. Infection of ccr5∆32 CD4+ T
cells by three of the R5X4 Envs was completely inhibited by AMD3100, while Env
CRPE.B28.4072 could infect ccr5Δ32 cells in the presence of AMD3100, though with
reduced efficiency (data not shown). However, we found that AMD3100 inhibited
infection of NP2/CD4/CXCR4 cells by viruses bearing the CRPE.B28.4072 Env by only
50%. In addition, this Env was unable to infect NP2 cells expressing CD4 alone or in
combination with any of 17 different putative alternative coreceptors, indicating that this
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Env can utilize the drug-bound conformation of CXCR4 (data not shown). Several other
HIV-1 Env proteins have been shown to exhibit this property [52]. In su mmary, all T/F
Envs utilized CCR5, while three were R5X4-tropic. Thus, there were no differences in
coreceptor tropism between the T/F and chronic Envs with the exception of the one X4tropic chronic Env, and there was no evidence for utilization of coreceptors other than
CCR5 or CXCR4 to infect human CD4+ T cells.
Sensitivity to coreceptor antagonists and CCR5 utilization efficiency.
Mucosal transmission of HIV-1 is dependent upon CCR5. Hypothesizing that the ability
to use low levels of CCR5 may confer selective advantage to viruses at the moment of
transmission, we determined the sensitivity of each Env to the CCR5 inhibitor maraviroc
(MVC) as a surrogate for CCR5 utilization efficiency. High MVC IC50 values indicate
that an Env can mediate infection at low levels of CCR5, while low IC50 values suggest
an Env requires high CCR5 expression for viral entry. We found no significant
difference in median MVC IC50 values between the T/F (2.4 nM) and chronic Envs (2.3
nM) (p=0.79; Mann-Whitney) (Figure 2-2A). In addition, we determined the maximal
percent inhibition (MPI) of infection by MVC. While uncommon, several in vivo derived
MVC-resistant R5-tropic viruses have been identified that can utilize the drug-bound
form of CCR5 [53,54]. Such viruses engage the coreceptor differently, relying
predominantly upon the N-terminus for entry whereas most viruses require the Nterminus as well as the extracellular loops of CCR5. Furthermore, determining the MVC
sensitivity of T/F viruses has implications for microbicides and pre-exposure prophylaxis.
All 41 Envs examined had MPIs greater than 85%, with the vast majority greater than
95%. There were no significant differences (p=0.17 Mann-Whitney) between the T/F
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(median= 99.1%) and chronic Envs (median=98.3; Figure 2-2B). Together, these data
indicate that the HIV-1 transmission bottleneck does not impose a selection pressure for
viruses capable of using low concentrations of CCR5.
Primary CD4+ T cell tropism. CD4+ T cells, the major target and source of
HIV-1 in vivo [55,56], can be broadly divided into four subsets: naïve (CCR7+CD45RO), central memory (TCM) (CCR7+CD45RO+), effector memory (TEM) (CCR7CD45RO+), and CD45RA+ in part to variation in coreceptor expression [57], cellular
activation [58], and tissue localization [59]. TEM and TEMRA cells are found predominantly
in effector sites including the rectal and cervicovaginal mucosa, while naïve and TCM
cells are most abundant in the lymph nodes. TEM cells, the most abundant subset in
mucosal effector sites, are preferentially infected and massively depleted during acute
infection (reviewed in [60]). Since potential target cells in the mucosa may be limiting
during transmission, we hypothesized that T/F Envs may infect TEM and TEMRA cells
preferentially relative to the matched chronic controls.
Peripheral blood CD4+ T cells from three normal uninfected donors were purified
by negative selection and stimulated with anti-CD3/anti-CD28 and IL-2 for three days
prior to infection with HIV-1 pseudotypes expressing a GFP reporter. Three days postinfection, viability and expression of CD3, CD4, CCR7, CD45RO, and GFP was assessed
by FACS analysis. Productively infected cells were defined as CD3+ GFP+ since CD4
was down-regulated in the majority of infected cells [61]. The gating strategy is shown in
Figure 2-3A. In all three donors, infected cells were predominantly TEM (~65%),
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Figure 2-2. CCR5 utilization efficiency. (A) Viral pseudotypes were used to infect
NP2/CD4/CCR5 cells in the presence of serial dilutions of the CCR5 antagonist
maraviroc (MVC). Higher IC50 values correspond to Envs that can utilize CCR5 more
efficiently, and vice versa. T/F and chronic clade B Envs have similar MVC IC50 values
(p=0.79) suggesting they engage CCR5 comparably. (B) Since some Envs can utilize the
MVC-bound conformation of CCR5 and since MVC is a candidate microbicide, we
assessed the maximal percent inhibition (MPI) of MVC for each Env. All Envs were
sensitive to MVC and there was no difference in MPI between the T/F and chronic Envs
(p=0.17). All infections were done in at least triplicate in each of at least three
independent experiments. Data was analyzed by a Mann-Whitney test.
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tropic viruses have been previously reported to readily infect naïve CD4+ T cells
compared to R5-tropic viruses [62,63,64], this assay contains an important internal
validation: the five viruses that could utilize CXCR4 for entry (one X4-tropic Env shown
in cyan; four R5X4-tropic Envs shown in red) preferentially infected naïve cells. With
the exception of these five Envs, no other pseudotypes were reproducibly outliers in their
ability to mediate entry into any of the subsets, and there were no statistically significant
differences or trends between the T/F and chronic Envs for any of the four cell subsets in
any of the three donors examined (Figure 2-3B). In addition, there was no statistically
significant difference in overall infectivity between the T/F and chronic Env pseudotypes
in any of the three donors examined suggesting comparable Env fitness in peripheral
CD4+ T cells (Figure 2-3C). Together, this suggests that transmission and early
expansion is not due to differential infection of CD4+T cells or their subsets between T/F
and chronic Envs.
DC-mediated trans-infection. DCs can enhance HIV-1 infection in trans by
efficiently capturing virus particles and presenting them to CD4+ T cells. In vitro, coculture of monocyte-derived DCs with CD4+ T cells results in enhanced virus infection,
particularly at low virus inocula (reviewed in [65]). To assess whether DCs preferentially
bind and transfer T/F compared to chronic Env pseudoviruses, we performed DC:CD4+
T cell co-culture experiments. Viral pseudotype stocks were normalized for infectivity on
NP2 cells to control for differences in viral titer. A relatively limiting amount of virus (80
RLUs on NP2 cells) was bound to DCs, which were then washed to remove cell-free
virus and co-cultured with CD4+ T cells. All Envs were assessed in at least three
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Figure 2-3. CD4+ T cell subset tropism. To assess human CD4+ T subset tropism of the
T/F and chornic Envs, cells were infected with Env pseudotypes expressing GFP and then
stained and analyzed by flow cytometry. (A) Cells were gated as shown. Infected cells
(GFP+) were then back-gated on the memory markers CCR7 and CD45RO to evaluate
differential subset infection. Naïve (CCR7+CD45RO-); central memory (TCM)
(CCR7+CD45RO+); effector memory (TEM) (CCR7-CD45RO+), effector memory RA
(TEMRA) (CCR7-CD45RO-). (B) T/F and chronic Envs infected all four CD4+ T cell
subsets comparably. TEM and TCM cells were infected most readily followed by naïve and
TEMRA cells. As expected, Envs that could utilize CXCR4 preferentially infected naïve
cells compared to Envs that used exclusively CCR5. (C) T/F and chronic Env
pseudotypes have comparable overall CD4+ T cell infection frequency in each of the
three donors examined. R5X4-tropic Envs are shown in red and the one X4-tropic Env is
shown in cyan. R5X4-tropic Envs are shown in red and the one X4-tropic Env is shown
in cyan. Tropism was assessed in cells obtained from three different, uninfected normal
donors as indicated (ND218, ND335, and ND337). The horizontal lines indicate the mean
value for each group of Envs.
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independent experiments, each time using DCs and CD4+ T cells from different normal
donors. Adding this amount of virus to 3x104 CD4+ T cells, then washing as with the
DCs, resulted in infection at background levels. However, adding virus associated with
DCs markedly increased infection. Nonetheless, the magnitude of DC:CD4+ T cell
trans-infection was not different between T/F and chronic Envs (Figure 2-4; p=0.44
Mann-Whitney). In addition, there was no difference in CD4+ T cell infectivity in the
absence of DCs and there was no detectable infection of DC control cultures in the
absence of CD4+ T cells (data not shown). The absence of any difference between T/F
and chronic pseudoviruses in this trans-infection assay suggests that, at least when
presented with an equal amount of infectious pseudovirus, DCs bind and transfer T/F and
chronic Env pseudotypes similarly.
Entry kinetics and enfuvirtide sensitivity. Productive entry of HIV-1 into cells
may occur following internalization and delivery to endosomes, albeit in a pHindependent manner [66]. If so, then the rate at which a virus is internalized, fuses, and
enters cells could impact viral tropism. In addition, the rate at which a virus fuses is a
measure of how well it productively engages CD4 and coreceptor. Hypothesizing that
faster-fusing viruses may preferentially overcome mucosal barriers to transmission, we
indirectly assessed the entry kinetics of the T/F and chronic pseudoviruses using a timeof-addition experiment with the fusion inhibitor enfuvirtide. As enfuvirtide is not
membrane permeable, time to enfuvirtide escape may reflect the rate of viral endocytosis,
fusion, or some combination thereof. HIV-1 pseudotypes were added to NP2 cells on ice.
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Figure 2-4. Dendritic cell (DC) trans-infection. To assess differential DC-binding and
CD4+ T cell trans-infection of T/F and chronic Envs, we pulsed DCs with luciferase
expressing Env pseudotypes and then washed off unbound virus and added CD4+ T cells.
Relative light units (RLUs) were then measured as a surrogate for infection. DC transinfection efficiency was comparable between the T/F and chronic Envs (p=0.44). Viral
input was normalized based upon infectivity on NP2 cell lines. Data shown is from one of
at least three independent experiments with cells from different donors, each done in at
least triplicate. Data was analyzed by a Mann-Whitney test.
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Cells were spinoculated at 4°C to facilitate HIV-1 binding and then cold media
was removed and replaced immediately with pre-warmed media. Saturating
concentrations of enfuvirtide were then added at 0, 5, 10, 20, 40, 80, and 160 minutes
post-warming, and then infectivity was normalized to a no-drug control. To control for
experimental variation, the prototypic R5-tropic virus JRFL was included in all
experiments. There was no significant difference or trend in the rate at which T/F and
chronic Env pseudotypes productively entered NP2 cells, thus becoming resistant to
enfuvirtide addition. The median time to half maximal resistance (t ½ max) postwarming was 32.5 minutes for the T/F and 31.4 minutes for the chronic Envs (p=0.55
Mann-Whitney). Interestingly, JRFL became resistant to enfuvirtide significantly faster (t
½ max= 15.9 minutes) than all 41 T/F and chronic Envs (Figure 2-5A). In addition, we
assessed enfuvirtide potency, a measure of pre-hairpin bundle exposure that also reflects
kinetics of CD4/coreceptor engagement and endocytosis [67]. There was no difference
between T/F and chronic Env sensitivity to enfuvirtide (mean IC50 0.10 vs 0.13 µg/ml;
p=0.53; Figure 2-5B). Together this suggests that the kinetics of viral entry/endocytosis
are comparable between T/F and chronic Envs.
Sensitivity to broadly neutralizing antibodies and HIV Ig. It has previously
been reported that Envs derived from acutely infected individuals may exhibit enhanced
sensitivity to antibody-mediated neutralization because of changes in glycosylation
and/or variable loop length [2]. This finding raised the possibility that such Envs might
be able to bind to CD4 and coreceptor more efficiently. To examine this, we measured
the sensitivity of the T/F and chronic Envs to four broadly neutralizing MAbs. MAbs b12
[41] and VRC01 [68] neutralize Env by engaging the CD4 binding site (CD4bs), while
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the epitopes for PG9 and PG16 [69], distinct germ-line variants from the same individual,
are glycosylation-dependent and include parts of the V1/2 and V3 loops [70]. To assess
neutralization sensitivity, pseudoviruses were pre-incubated with a single concentration
(10 µg/ml) of each MAb for 60 minutes prior to infection of NP2 cells. Maximal percent
inhibition was then determined by normalizing to a control without antibody.
Interestingly, T/F Envs were more sensitive than chronic Envs to both b12 (mean
MPI 66% vs. 17%; p=0.0003; Figure 2-6A) and VRC01 (mean MPI 89% vs. 50%;
p=0.0077; Figure 2-6B compare T/F to Chronic 1). There was also a trend towards
enhanced sensitivity to neutralization by PG9 (Figure 2-6C) and PG16 (Figure 2-6D). To
confirm these differences, the neutralization sensitivity of T/F Envs was independently
examined using a different backbone (SG3) and HIV-1 reporter cell line (TZMbl), with
both MPI and IC50 values being determined. The results confirmed the NP2 cell data in
that the T/F Envs were more sensitive to neutralization by b12 (Figure 2-6E) and VRC01
(Figure 2-6F). In addition, the T/F Envs exhibited a trend towards increased
neutralization sensitivity to both PG9 (Figure 2-6G) and PG16 (Figure 2-6H). While this
did not reach statistical significance, it is consistent with a more neutralization sensitive
phenotype of T/F compared to chronic Envs.
To assess whether the neutralization sensitive phenotype of our T/F Envs
depended on the particular panel of chronic Envs used, we examined the neutralization
sensitivity of 14 clade B control Envs derived from six additional chronically infected
individuals (Chronic 2 in Figure 2-6A-D). Similar to the initial test set of chronic Envs
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Figure 2-5. Entry kinetics and enfuvirtide sensitivity. (A) To examine differences in
T/F and chronic Env endocytosis/fusion kinetics, we employed an indirect assay in which
viral pseudotypes were bound to NP2 cells in the cold prior to the addition of pre-warmed
media. A saturating concentration of enfuvirtide was added at various times postwarming. The time to half-maximal resistance to enfuvirtide (t ½ max) was then
calculated. The T/F and chronic Envs became resistant to enfuvirtide at equal rates
(p=0.55), with all of the Envs acquiring resistance to enfuvirtide more slowly than a
prototypic R5-tropic HIV-1 control, JRFL. (B) Enfuvirtide potency, a compound measure
of fusion kinetics and affinity, was assessed for all T/F and chronic Envs. There was no
difference in enfuvirtide IC50 between the T/F and chronic Envs (p=0.53) further
suggesting there is no difference in endocytosis/fusion rates between T/F and chronic
Envs. Each infection condition was done in triplicate (A) or duplicate (B) for each Env in
each of at least three independent experiments. Data was analyzed by a Mann-Whitney
test.
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(Chonic 1 in Figure 2-6A-D), this validation set exhibited increased resistance to b12
compared to T/F Envs (p=0.0001 Mann-Whitney). However, unlike the initial chronic
Env panel, the validation Envs were similar to the T/F Envs in their sensitivity to VRC01
(p=0.14 Mann-Whitney). Finally, there were no differences in PG9 and PG16 sensitivity
between the T/F and the validation Envs (Figure 2-6C, D).
While broadly neutralizing MAbs are useful tools in examining neutralization
sensitivity, they are rare in HIV-1-infected individuals and thus may give a biased view
of HIV-1 neutralization. Thus, we examined neutralization sensitivity of the T/F and
chronic Envs to pooled sera from patients infected with clade B HIV-1 strains (clade B
HIV Ig). The T/F Envs (median IC50 741 µg/ml) were approximately two-fold more
neutralization sensitive than the chronic test panel (median IC50= 1179 µg/ml p=0.062),
the chronic validation panel (median IC50 =1500 µg/ml p=0.0095), and the combined
clade B chronic panel (median IC50 1324 µg/ml p=0.0078; Figure 2-6I).
To examine the basis for the enhanced b12 and VRC01 neutralization sensitivity
of T/F Envs, we measured the binding of the two MAbs to both T/F and chronic Envs.
Binding to the trimeric form of the Env expressed on the surface of cells was measured
using a cell-based ELISA system [44]. To obtain an accurate measure of antibody
binding affinity, we corrected binding measurements for the level of cell surface
expression of the different Envs. For this purpose, the binding efficiency of b12 and
VRC01 was expressed as a fraction of the binding of a CD4-Ig probe added at saturating
concentrations. CD4-Ig is a fusion protein that consists of two copies of the two Nterminal domains of CD4 that are linked to the Fc region of human IgG1.
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Figure 2-6. Neutralization sensitivity. The sensitivity to monoclonal antibodies b12,
VRC01, PG9, and PG16 was assessed on both NP2 cells (A-D) and TZMbls (E-H).
Neutralization sensitivity on NP2 cells was assessed by determining the maximal percent
inhibition (MPI) to 10µg/ml of the indicated MAb. IC50 values were determined in the
TZMbl assay. Clade B T/F Envs were more sensitive to b12 and VRC01 compared to the
geographically-matched panel of chronic Envs (Chronic 1). To confirm this finding, we
assessed an independent panel of clade B chronic Envs from Washington state (Chronic
2). “All chronic” includes clade B chronic panels 1 and 2. (I) Clade B T/F Envs are also
more sensitive to clade B HIV Ig on NP2 cells as measured by IC50. P-values shown are
from Mann-Whitney tests with the corresponding T/F Envs. NP2 and TZMbl
experiments were performed in at least three and two independent experiments,
respectively.
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For the entire group of Envs (i.e., T/F and both chronic Envs groups combined), a
very strong correlation was observed between the binding of the MAbs to the trimeric
Envs and their sensitivity to inhibition. Spearman rank-order correlation coefficients of
0.62 (p<0.0001) and 0.77 (p<0.0001) were obtained for b12 and VRC01, respectively
(Figure 2-7A and B). Comparison of MAb binding to the T/F and chronic Envs showed
clear differences between the two groups for both b12 and VRC01. Binding of b12 to the
T/F Envs was significantly increased relative to both groups of chronic Envs (Figure 27C). Binding of VRC01 to the T/F Envs was increased relative to the original group of
chronic Envs (p=0.004; Figure 2-7D). The differential formation/exposure of these
epitopes suggests the existence of at least modest structural differences within or near the
CD4-binding site of T/F and chronic Envs. No significant differences were observed
between VRC01 binding to the T/F and the Washington Envs (p= 0.21).
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Figure 2-7. Correlation between MAb binding and neutralization. Env was expressed
on the surface of cells and then binding to b12 (A) and VRC01 (B) was assessed relative
to a CD4 control by ELISA. There is a strong positive correlation between binding and
Env pseudotype neutralization sensitivity for both b12 and VRC01 for the T/F and both
panels of chronic Envs serving to validate the assay. To assess the mechanism of
enhanced neutralization sensitivity, we compared b12 (C) and VRC01 (D) binding
between T/F and chronic Envs. This suggests that differences in MAb binding explain
neutralization differences between T/F and chronic Envs. Data shown is the mean of two
independent experiments.
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Discussion
The genetic bottleneck that occurs during mucosal transmission of HIV-1 results
from the fact that most often only a single founder virus is successfully transmitted from
amongst a diverse swarm of viruses present in the donor [1]. It is evident that a
significant degree of selection is manifest at this step since transmission of R5-tropic
virus strains is far more efficient than that of X4-tropic and even R5X4-tropic viruses
[6,71]. Whether there is selection for additional viral phenotypes beyond coreceptor use
or whether viral transmission is essentially a stochastic process, in which any reasonably
fit R5-tropic HIV-1 strain can be transmitted, has not yet been determined. Addressing
this question is of practical importance since properties associated with preferential viral
transmission could potentially be exploited by vaccine or other antiviral approaches.
Genetic, immunologic, and phenotypic signatures associated with transmitted
HIV-1 Envs have been sought in a number of previous studies, most entailing Envs
obtained from early infections (acute Envs) [2,3,6,19,20,24,26] as opposed to true T/F
Envs obtained by SGA analyses [1,17,28]. Several studies concluded that T/F and acute
Envs have on average shorter variable loops and fewer PNGs than Envs derived from
chronically infected individuals [2,3]. While such differences have been noted for Envs
from multiple HIV-1 clades, they are relatively subtle, variable in location and far from
predictive, with some being evident only when larger numbers of sequences are
compared. The 24 T/F Envs examined here, for example, exhibited no consistent genetic
differences from the chronic controls. Nonetheless, a much larger sequence comparison
that included all but one of the envs examined here identified a small number of sequence
signatures associated with transmission, including specific sites in the signal sequence
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and gp41 cytoplasmic domain that could affect Env processing, localization, and
incorporation into virus particles as well as changes in the receptor binding regions in
gp120 and in N-linked glycosylation sites (Gnanakaran, et al, submitted). Thus, existing
evidence points to an array of genetic features that may be associated with enhanced
HIV-1 transmission across mucosal surfaces by unknown mechanisms.
The identification of genetic motifs in env that are enriched in T/F viruses is
consistent with the possibility that specific phenotypic properties can be identified that
might provide a selective advantage to transmitted viruses. This is clearly the case at a
global level, in that T/F Envs are almost invariably R5-tropic and replicate well in CD4+
T cells but poorly in monocyte-derived macrophages (with the exception of clade D
viruses, G.M. Shaw and J. Baalwa, unpublished data) [28]. More detailed phenotypic
studies of recently transmitted viruses are generally lacking, although donor and recipient
Envs from eight transmission pairs exhibited no differences in CD4 or CCR5 utilization,
while a second study using some of these same Envs did not find consistent differences in
primary cell infection or use of receptors other than CCR5 and CXCR4 [19,20]. As
genetic signatures associated with transmission can be both variable and subtle, we
employed a more detailed series of functional assays to seek differences between viral
pseudotypes bearing the T/F Envs and those expressing Envs from chronic controls. We
found no phenotypic differences between the T/F and chronic Envs examined here in
assays designed to probe the efficiency and rate of membrane fusion, the efficiency of
coreceptor use, the ability to infect primary CD4+ T cell subsets from different donors,
and the ability of virus to be captured by DCs and transferred to adjoining CD4+ T cells.
One could ask whether the assays we employed are sufficiently sensitive to detect
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functional differences between viruses bearing different Env glycoproteins. We feel that
they are, as we and others have used these and similar assays to identify significant
functional differences between Envs at the level of primary CD4+ T cell tropism,
membrane fusion kinetics, the efficiency of CD4 and co-receptor utilization, and
attachment to C-type lectins such as DC-SIGN [11,12,13,14]. Even single amino changes
in Env can impact these properties to extents that can be easily detected. The CD4+ T cell
subset tropism assay that we have developed, which can determine the efficiency with
which a given virus infects TCM, TEM, TEMRA and naïve T cells, is a particularly sensitive
measure of CD4 and coreceptor use, as these receptors are expressed differently on
various CD4+ T cell subsets [57,72,73,74,75]. The fact that that 24 T/F Envs here were
functionally equivalent to the chronic Env controls in all of the assays employed argues
that any phenotypic differences between these and chronic Env controls are apt to be
slight in magnitude.
A second consideration regarding the presence or absence of phenotypic traits
associated with enhanced virus transmission is whether the assays we employed
effectively recapitulate the key events during the earliest stages of HIV-1 transmission
(reviewed in [76]). Following mucosal transmission of HIV-1, virus is not detected in the
circulation for about 10 days, a period termed the eclipse phase (reviewed in [77]).
Detailed studies in the macaque model show that after vaginal exposure small clusters of
infected cells are found in the endocervical region, which is lined by a single layer of
epithelial cells [56]. The recruitment of plasmacytoid DCs, T cells, and macrophages
over several days transforms the initial focus of infection into a CD4+ T cell-rich
environment. Similar studies have not yet been conducted assessing penile or rectal
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transmission in the rhesus model, the likely mode of transmission in the predominantly
male cohort assessed in this study. Conceivably, Env properties that promote entry into
resting and activated CD4+ T cells in the submucosa as well as transmission between
cells could increase the possibility that an initial focus of infection will successfully
propagate and eventually lead to dissemination to regional lymph nodes and a systemic
infection. The CD4+ T cell subset tropism assay we employed, while more detailed and
sensitive than bulk CD4+ T cell infection assays, may not produce CD4+ T cells with
properties identical to those found in the rectal or cervicovaginal mucosa. In addition, the
DC:CD4+ T cell transmission assay we used is but a surrogate for the likely more
complex cell-cell interactions found in the initial foci of infection. It is important to keep
in mind that since virus appears to replicate locally for a period of at least a few days to a
week, even a relatively subtle change in an Env property that might enhance infection
could result in a significant selective advantage over the course of multiple rounds of
infection. The single-cycle assays we employed, while sensitive and well-validated,
cannot capture the impact of more subtle differences in Env fitness over time. Future
studies employing T/F infectious molecular clones in both primary cell and tissue explant
cultures might be better suited for the identification of early fitness differences associated
with T/F viruses.
In addition to genetic signatures, differences at the level of sensitivity to antibodymediated neutralization have been found in some studies of recently transmitted viruses
[1,2]. We found that the panel of clade B T/F Envs was more sensitive to the CD4
binding site MAbs b12 and VRC01 as well as clade B HIV Ig, but not to the broadly
neutralizing antibodies PG9 and PG16. These differences were approximately two-fold in
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magnitude and partially dependent upon the control group employed. Specifically, when
a second panel of chronic Envs was used as a control, enhanced sensitivity to VRC01 was
not observed, though MAb b12 and clade B HIV Ig continued to neutralize the T/F Envs
more efficiently. The relatively modest differences that were observed, along with the
fact that enhanced neutralization was not seen between all study groups raises several
important questions: do T/F Envs exhibit features that generally enhance their sensitivity
to certain types of neutralizing antibodies, and if so, what is the basis for these
differences and what are the implications for virus transmission?
One limitation of this study is the selection of chronic control Envs. Ideally,
chronic control Envs would be selected from longitudinal samples or confirmed
transmission pairs; however, such samples are difficult to find in sufficient numbers,
especially since the great majority of acute clade B infections are treated with antiretroviral therapy. It would also be preferable to obtain chronic Envs from semen or
genital secretions, the likely source of the viral inoculum, but again such samples are
exceedingly scarce. In addition, the majority of Envs used in this study were from males
who likely acquired HIV by penile or rectal transmission. Thus, further work is needed
to characterize the transmission bottleneck that occurs during vaginal transmission. Our
results emphasize the importance of selecting appropriate matched chronic controls since
the chronic test and validation sets differed in their neutralization profiles to VRC01
(though not to MAb b12 and clade B HIV Ig) despite no obvious differences in length of
infection, transmission risk factor, patient demographics, or phylogenetic relationships to
the T/F Envs. Of course, since we are unable to reliably predict neutralization sensitivity
from sequence information alone, a control group could by chance differ
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immunologically from the T/F Envs despite being otherwise well-matched. To mitigate
this, selecting chronic Env controls from geographically-matched individuals may be
important. For example, we previously reported that clade B T/F Envs are more resistant
than chronic Envs to b12 and the membrane proximal external region (MPER) antibodies
2F5 and 4E10 [1], seemingly in contradiction with our current findings. However, reexamination of the data in Keele et al. showed that this was due to the predominance of
neutralization-sensitive Envs derived from chronically-infected individuals in Trinidad.
These Trinidad Envs form a subcluster within the other clade B Envs used in this study
(Figure 2-1), have a Thr deletion in the V3 loop compared to the clade B consensus, were
over-represented in the chronic controls and were more sensitive to neutralization by
MAbs b12, 2F5 and 4E10 [50]. Thus, the previous 2F5 and 4E10 neutralization
difference between T/F and chronic Envs was due to bias resulting from disproportionate
representation of Envs from Trinidad in the chronic controls.
Several other studies that have assessed neutralization sensitivity of clade B Envs
did not use geographically-matched chronic controls, raising the possibility that the
results from theses studies could be complicated by genotypic differences linked to
geographic location [25,69,78]. In addition to the location, it may also be important to
match the time of sample collection when developing well-matched chronic control
groups. For example, Bunnik et al. reported that HIV-1 has become more neutralization
resistant over the course of the epidemic and thus patient sampling times may bias
comparisons between T/F and chronic Envs [79]. Here, the chronic Envs were sampled
four calendar years before the T/F Envs on average. However, this difference is
significantly shorter than the 14-21 year time-span between contemporary and historic
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Envs assessed in Bunnik et al. In addition, we detected no correlation between sampling
time and neutralization sensitivity, and thus this cannot account for the neutralization
differences between the T/F Envs and the chronic controls. It is also of note that multiple
chronic Envs from the same individual were treated as independent events in this study.
Reanalyzing the data to include only one chronic Env value (mean of the multiple Envs)
per individual did not change the magnitude of the neutralization difference, though it did
decrease the p-values above the level of significance for VRC01 and HIV Ig, but not b12,
likely due to decreased sample size. In summary, more detailed studies involving larger
numbers of T/F Envs with appropriately matched control Envs, including Envs derived
from the same individuals over time, and a greater number of broadly neutralizing MAbs
and human sera, will be needed to draw definitive conclusions about the neutralization
sensitivity of transmitted virus strains.
When our data are considered along with other published studies on T/F and acute
Envs, several conclusions can be drawn. First, we believe that HIV-1 transmission is in
part stochastic, with any reasonably fit R5-tropic virus being capable of initiating an
infection [1,6,9,10]. With a now relatively large number of T/F and acute Envs having
been examined, it is evident that no single major genetic, phenotypic or immunologic
signature is required for transmission beyond the use of CCR5. Second, an array of
genetic traits including but not limited to shorter variable loops and reduced numbers of
N-linked glycosylation sites are associated with enhanced virus transmission. The
structural implications of these signatures are not well understood, and it is not yet clear
if these or as yet unidentified other genetic traits are responsible for the modestly
enhanced sensitivity to antibody-mediated neutralization that is characteristic of some
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T/F and acute Envs. Third, the presence of genetic signatures linked to transmission
implies some impact on function that enhances transmission. If so, then the functional
impact is apt to be modest given the variable nature of the genetic signatures and the fact
that neither we, nor others, have observed clear differences between T/F and acute Envs
with chronic controls. However, the possibility exists that relatively subtle alterations of
Env function, perhaps in the context of full-length T/F viral genomes, could provide a
sufficiently robust selective advantage during the eclipse phase of HIV-1 transmission to
result in preferential transmission of viruses with specific properties. The growing
application of SGA technology coupled with increasingly sophisticated cell-to-cell and ex
vivo tissue systems will make it possible to more rigorously identify immunologic and
phenotypic traits associated with HIV-1 transmission.
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Abstract
HIV-1 entry requires the cell surface expression of CD4 and either the CCR5 or
CXCR4 coreceptors on host cells. Individuals homozygous for the ccr5∆32
polymorphism do not express CCR5 and are protected from infection by CCR5-tropic
(R5) virus strains. As an approach to inactivating CCR5, we introduced CCR5-specific
zinc-finger nucleases into human CD4+ T cells prior to adoptive transfer, but the need to
protect cells from virus strains that use CXCR4 (X4) in place of or in addition to CCR5
(R5X4) remains. Here we describe engineering a pair of zinc finger nucleases that, when
introduced into human T cells, efficiently disrupt cxcr4 by cleavage and error-prone nonhomologous DNA end-joining. The resulting cells proliferated normally and were
resistant to infection by X4-tropic HIV-1 strains. CXCR4 could also be inactivated in
ccr5∆32 CD4+ T cells, and we show that such cells were resistant to all strains of HIV-1
tested. Loss of CXCR4 also provided protection from X4 HIV-1 in a humanized mouse
model, though this protection was lost over time due to the emergence of R5-tropic viral
mutants. These data suggest that CXCR4-specific ZFNs may prove useful in establishing
resistance to CXCR4-tropic HIV for autologous transplant in HIV-infected individuals.
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Introduction
For HIV to infect cells, the viral envelope (Env) protein must bind to the host
protein CD4 and then to a coreceptor, most commonly CCR5 (R5 HIV) (reviewed in [1]).
The importance of CCR5 for HIV-1 pathogenesis is shown by the fact that individuals
who are homozygous for an inactivating 32 base pair deletion in ccr5 (ccr5∆32) are
highly resistant to HIV infection [2, 3], while heterozygotes typically live longer after
HIV infection due to reduced CCR5 expression levels [4, 5]. Recently, an HIV infected
patient with acute myelogenous leukemia received a bone marrow transplant from a
ccr5∆32 homozygous donor [6]. This patient’s viral load remains undetectable even in
the absence of anti-retroviral therapy more than three years post-transplant, suggesting
that this individual's HIV infection has been eradicated. In theory, the success of this
approach could be recapitulated by inhibiting CCR5 with an orally bioavailable small
molecule such as maraviroc, which binds to CCR5 and prevents its use by most R5 HIV1 strains. However, virus strains that can utilize CXCR4 either in place of (X4 HIV) or in
addition to CCR5 (R5X4 HIV) are found at significant levels in roughly 50% of latestage infected individuals [7, 8], supporting the need for therapies targeted to CXCR4 [9].
Ideally, an approach to target CXCR4 would complement CCR5-specific therapy, but the
broad expression pattern of CXCR4 has made systemic inhibition of this coreceptor by
small molecules problematic [10, 11]. In addition, resistance to CCR5 and CXCR4
antagonists can arise in patients by mutations in the viral envelope protein (Env) that
enable it to utilize the drug-bound forms of these coreceptors [12-16]. The ability of HIV1 to adapt to new selective pressures and the plasticity with which Env interacts with its
coreceptors argues for approaches that reduce or eliminate coreceptor expression rather
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than simply altering coreceptor conformation. If approaches could be developed that
specifically target expression of both CCR5 and CXCR4 on CD4+ T cells, virus entry
should be inhibited more effectively.
Several genetic approaches have been taken to reduce or eliminate CCR5
expression in human cells, including the use of ribozymes [17, 18], single-chain
intracellular antibodies [19], trans-dominant coreceptor mutants [20], and RNAi [21, 22].
However, these studies are limited by the requirement for stable expression of an
exogenous gene. To circumvent this, a CCR5 specific zinc-finger nuclease pair (R5ZFNs) has been developed [23]. Zinc finger proteins that recognize a specific 24bp DNA
sequence are fused with a monomeric cleavage domain from FokI endonuclease that
functions only as a dimer. For DNA cleavage to occur, two zinc finger proteins must
bind, each to specific, adjoining sequences in the CCR5 gene, leading to FokI
dimerization and subsequent DNA cleavage resulting in a double strand break [24-26].
The double strand break then can be repaired by error-prone non-homologous end joining
(NHEJ) often introducing insertions and deletions leading to a non-functional gene
product when this break is placed within the coding region of the targeted gene [27].
Following introduction into human CD4+ T cells [23] or hematopoietic stem cells [28]
via an adenovirus vector or DNA nucleofection, respectively, the ccr5 gene was
efficiently and specifically disrupted. This confers protection in vitro and in humanized
mice to infection by HIV-1 isolates that require CCR5 (but not CXCR4). Several early
stage clinical trials using autologous infusions of ZFN-generated CCR5-modified CD4+
T cells are currently underway (clinicaltrials.gov identifiers NCT00842634,
NCT01252641, NCT01044654).
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In this study we describe the design and pre-clinical evaluation of a CXCR4specific ZFN pair (X4-ZFNs) that specifically and efficiently disrupts cxcr4, rendering
human CD4+ T cells permanently resistant to HIV-1 strains that require CXCR4 for
infection. We also demonstrate that cxcr4 can be safely and efficiently disrupted in CD4+
T cells obtained from ccr5∆32 homozygotes resulting in cells resistant to all strains of
HIV-1 tested. This suggests that combined treatment of mature CD4+ T cells with X4ZFNs and R5-ZFNs can provide permanent protection against HIV-1 infection.
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Materials and Methods
Zinc-finger nuclease constructs. We designed ZFNs specific to the human and
rhesus CXCR4 and CCR5 genes using a previously described approach [29]. One ZFN
pair was used to target both the human and rhesus macaque CXCR4 genes since the 24
bp target sequences are identical. Zinc-finger proteins were optimized against the target
gene sequence and assembled as described [30] from an archive of in-vitro-selected
modules [31, 32]. The ZFP moieties (target gene; ZFP name; target sequence (5’3’);
recognition α-helices (finger number)) are as follows: CXCR4; X4-ZFN-L;
GTAGAAGCGGTC, DRSALSR (1), RSDDLTR (2), QSGNLAR (3), QSGSLTR (4);
CXCR4; X4-ZFN-R; GACTTGTGGGTG, RSDSLLR (1), RSDHLTT (2), RSDSLSA
(3), DRSNLTR (4). Rhesus CCR5; rhR5-ZFN-L; GATGAGGACGAC, RSDNLAR (1),
TSGNLTR (2), RSDNLAR (3), TSGNLTR (4); Rhesus CCR5; rhR5-ZFN-R;
AAACTGCAAAAG; RSDNLSV (1), QKINLQV (2), RSDVLSE (3), QRNHRTT (4).,
The human CCR5-specific ZFNs are described in Perez et al [23]. The Ad5/F35
adenoviral vectors were generated on an E1/E3 deleted backbone. The ZFNs targeting
either the cxcr4 or ccr5 genes were linked via a 2A peptide sequence and cloned into the
pAdEasy-1/F35 vector under control of the CMV TetO promoter, and the Ad5/F35 virus
for each construct was generated using TREx 293T cells as described [33]. The Ad5/F35
vector encoding the X4-ZFNs is identical to that use by Nilsson, et al. [33] except for the
ZFN inserts, promoter, polyA and linker sequences.
Cel1 (surveyor nuclease) assay. Genomic DNA was extracted with the
MasterPure kit (Epicentre Biotechnologies) according to manufacturer’s instructions.
Frequency of gene modification by NHEJ was evaluated as described previously [23, 25,
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28]. Briefly, the purified genomic DNA was used as a template to amplify a fragment of
the cxcr4 gene using the specific primers (human CXCR4: 5’CAACCTCTACAGCAGTGTCCTCATC -3’and 5’GGAGTGTGACAGCTTGGAGATG -3’; rhesus CXCR4: 5’GGTGGTCTATGTTGGAGTCTGG -3’and 5’- GGAGTGTGACAGCTTGGAGATG 3’) in the presence of a 32P-dATP and dCTP. The PCR products were then heated,
allowed to re-anneal followed by treatment with the mismatch-sensitive Surveyor
nuclease as described in order to detect insertions and deletions caused by NHEJ. For
humanized mice samples, whole genome amplification using the REPLI-g Mini Kit
(Qiagen) was conducted prior to the surveyor nuclease assay due to limiting cell
numbers.
Human CD4+ T cell stimulation and transduction. Fresh CD4+ T cells from
normal human donors, purified by negative selection, were obtained from the Center for
AIDS Research Human Immunology Core at the University of Pennsylvania. 2.5 million
CD4+ T cells were seeded at a density of 0.8 x 106 cells/ml in RPMI containing 10%
fetal calf serum, 1% penicillin/streptomycin, and 100U/ml interleukin-2 (IL-2). The cells
were stimulated with anti-CD3/anti-CD28 coated magnetic beads at a 3:1 bead to cell
ratio [34]. Approximately 18hrs post-stimulation, the cells were transduced with an
Ad5/F35 vector encoding either the X4-ZFNs or R5-ZFNs at a multiplicity of infection
(MOI) of 600. Beginning 72 hours post-stimulation, cells were counted every 48 hours
using trypan blue dye exclusion on an automated hemocytometer (Countess, Invitrogen)
and split to 0.8 x 106 with fresh media containing 100U/ml IL-2. Five days poststimulation, the magnetic beads were removed and washed twice in fresh media. Cells
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were counted and split until cell growth plateaued 10-14 days post stimulation. For longer
experiments, cells were restimulated with beads and cultured for an additional 10-14
days.
In vitro HIV-1 challenge of CD4+ T cells treated with AdX4-ZFNs. Five days
post-stimulation the anti-CD3/anti-CD28 coated magnetic beads were removed from each
of the three cultures (non-transduced (NTD), AdX4-ZFNs, and AdR5-ZFNs) and 2.5
million cells were seeded in each of four cultures that were subsequently infected with
either Bk132 (primary X4 isolate), HxB2 (lab-adapted X4 isolate), R3A (R5X4 primary
isolate), or media only (mock). 100ng p24 of HIV-1 was used per million cells.
Flow cytometry. All staining was done at room temperature in FACS Wash
Buffer (1mM EDTA, 2.5% fetal calf serum in PBS) and all antibodies were from BD
Biosciences unless otherwise noted. 0.5-1.0 x106 cells were washed in PBS and stained
with Live/Dead Aqua (Invitrogen) for 10 min. Then, anti-CD4 PE Cy5.5 and antiCXCR4 APC (clone 12G5) were added and cells were stained for 20-30 minutes. Cells
were then washed and permeabilized per manufacturer’s protocol using Cytofix/cytoperm
(BD) and stained intracellularly for HIV gag with KC57-RD1 (Beckman Coulter). For
compensation, ArC beads (Invitrogen) were used for live/dead, and CompBeads (BD)
were used for all other fluorochromes. To detect wtCXCR4 and CXCR4Δ18 in 293T
transient transfection experiments, anti-CXCR4 APC (clone 12G5) and anti-CXCR4 PE
(clone 4G10) (Santa Cruz Biotechnologies) were used. All samples were run on an LSRII
(BD) and analyzed using FlowJo 8.8.6 (Treestar Inc).
Events were gated as follows: singlets (FSC-A by FSC-H), live cells (SSC-A by
Live/Dead), lymphocytes (FSC-A by SSC-A), CD3+CD4+ (CD3 by CD4), and then
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events were divided into CXCR4+ and CXCR4- populations based upon a fluorescence
minus one (FMO) control.
454 deep sequencing and cxcr4 analysis. Genomic DNA was isolated from
CD4+ T cells using the QIAamp DNA Micro Kit (Qiagen). For each condition, 200 ng
genomic DNA was then PCR amplified using Platinum Taq High Fidelity (Invitrogen)
using the following primers plus 454 adaptor sequences and 8 letter DNA barcodes:
CAACCTCTACAGCAGTGTCCTCATC (forward) and
GGAGTGTGACAGCTTGGAGATG (reverse). Cycle conditions were 95° for 5min,
then 30 cycles of 95° for 30sec, 55° for 3 sec, 68° for 30 sec, followed by 68° for 2 min.
Following PCR amplification the PCR product was analyzed on a 2% agarose gel and
then extracted and gel purified using Wizard SV Gel and PCR Clean-Up System
(Promega). Quant-iT dsDNA High-Sensitivity Assay Kit (Invitrogen) was then used to
determine the concentration of each bar-coded amplicon. DNA samples were then pooled
at an equimolar ratio and run on a Roche/454 GS FLX using standard chemistries at the
University of Pennsylvania’s DNA Sequencing Facility. Approximately 30,000-100,000
reads were obtained for each experiment. CXCR4 pyrosequencing data were assigned to
samples by DNA barcode. Any reads containing ambiguous base calls or without a
perfect match to barcode and primer were discarded. All remaining reads were aligned to
the CXCR4 reference sequence using Mosaik
(http://bioinformatics.bc.edu/marthlab/Mosaik). All deviations from the CXCR4
consensus sequence 40 base pairs up or downstream from the ZFN binding site were
determined. Any reads that did not extend across this region or that failed to align were
discarded. Reads containing only two or fewer substitutions were not classified as
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mutations as these likely represent sequencing artifacts. Next, background
pyrosequencing error, identified by an untransduced control sample, was subtracted from
each group of reads. For frameshift analysis, the sequencing error was determined and
subtracted for each individual insertion or deletion size.
To ensure sufficient sampling of diverse amplicons, at least 200ng gDNA was
used for CXCR4 analysis and at least 400ng gDNA was used for off-target site
amplification, representing the genomic DNA content of approximately 70,000 and
140,000 alleles, respectively. Determining genetic disruption frequency by both the Cel1
and 454 assays require the assumption that wild type and disrupted alleles are not
differentially amplified.
Systemic evolution of ligands by exponential enrichment (SELEX) and
determination of off-target sites. To empirically determine the DNA binding preference
of the X4-ZFNs, we employed SELEX as previously described [23]. Briefly, each ZFP
was HA-tagged and incubated with randomized DNA oligonucleotides and anti-HA Fab
fragments. Any DNA bound to the ZFPs was then isolated and amplified. The newly
amplified DNA was then used to repeat this process for a total of four rounds of
enrichment. The DNA pool was then sequenced at approximately 50x coverage to
generate a positional-weighted matrix. This matrix was then aligned to the human
genome with the following criteria: putative off-target sites could have up to six
mismatches compared to the SELEX consensus sequence, the ZFP pairs must be
separated by either 5 or 6 bps, and both ZFP homo- and heterodimers were considered.
Off-target sites were ranked and scored by multiplying the probability of each nucleotide
at each of the 12 positions of the positional-weighted matrix. The highest scores were
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then deemed most likely to be disrupted. 454 off-target site data was analyzed as
discussed previously [23].
NSG mice. NSG (NOD.Cg-PrkdcscidIl2rgtm1Wjl/Szj) mice, 8-9 weeks old at time of
initial injection, were derived from breeders purchased from The Jackson Laboratory
(Bar Harbor, ME). Animals were maintained in a defined flora animal barrier facility at
the University of Pennsylvania’s Stem Cell and Xenograft Core.
Human CD4+ T cells were isolated and stimulated as previously described and
then transduced with an Ad5/F35 vector expressing either the R5-ZFNs or the X4-ZFNs
at an MOI of 600. Cells were maintained as previously described. Ten days post
stimulation 107 modified cells resuspended in 100µL PBS were injected intravenously
into the tail vein of each mouse. 23 animals received cells treated with X4-ZFNs and 22
mice received cells treated with R5-ZFNs. Animals were randomized by age, sex, and
cage. Mice were maintained on the antibiotic Baytril (Bayer) for 24 hours post-injection.
To infect the mice with HIV-1, 105 autologous CD4+ T cells previously infected
with X4 HIV-1 strain Bk132 were injected into the tail vein of each mouse. Autologous
cells used to infect mice that were not transduced were obtained and stimulated
simultaneously as the initially engrafted cells. Five days post-stimulation cells were
infected with 100ng p24/million cells and then were cryopreserved four days postinfection. Cell engraftment was assessed 27 days post injection, and mice were infected
with HIV-1 the following day.
To obtain whole blood, mice were anesthetized with isoflurane and a capillary
tube was used to drain the retroorbital vein. Human CD4+ T cell counts were determined
by staining 50µl of whole blood in Trucount tubes (BD) with anti-CD45 FITC
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(Biolegend), anti-CD3 Qdot 655 (Invitrogen), anti-CD4 Alexa Fluor 700, anti-CD8
Pacific Blue (Biolegend), and anti-CXCR4 PE-Cy5. Human CD4+ T cells were defined
as CD45+CD3+CD4+CD8-.
At the time of sacrifice, a cardiac puncture was performed to obtain maximal
blood volume and then the spleen was harvested. Spleens were homogenized and
erythrocytes were lysed with ACK lysis buffer (Invitrogen) before cell purification.
Human CD4+ T cells were then isolated with the Human CD4 Positive Selection Kit
using the Robosep robotic cell separator (Stem Cell Technologies).
Rhesus macaque CD4+ T cell modification. Whole blood from rhesus
macaques (Macaca mulatta) housed at the Tulane National Primate Research Center was
used for CD4+ T cell isolation and ZFN treatment. Peripheral blood mononuclear cells
were isolated by centrifugation with 96% Ficoll (BD), followed by erythrocyte lysis with
ACK lysis buffer. CD4+ T cells were then isolated by negative selection with a nonhuman primate CD4+ T cell selection kit (Miltenyi). Cells were then stimulated with 1:4
anti-CD3 (clone FN-18)/ anti-CD28 (clone L293) M-450 tosylactivated beads
(Invitrogen) at a ratio of 1 bead per cell [35, 36].
Approximately 18 hours post-transduction, cells were transduced with an
Ad5/F35 vector expressing either the X4-ZFNs or rhesus specific R5-ZFNs. Cells were
maintained in culture as human CD4+ T cells. Surveyor nuclease assay was performed
six-ten days post transduction to assess disruption efficiency.
Ethics statement. Human CD4+ T cells were obtained after written informed
consent and approval by the University of Pennsylvania’s institutional review board. All
humanized mouse experiments were approved by the University of Pennsylvania’s
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Institutional Animal Care and Use Committee (Protocol 802436), and were carried out in
accordance with recommendations in the Guide for the Care and Use of Laboratory
Animals of the National Institutes of Health. All rhesus macaque experiments were
approved by the Tulane Institutional Animal Care and Use Committee approval (Protocol
P0085; Project 3520) The Tulane National Primate Research Center (TNPRC) is an
Association for Assessment and Accreditation of Laboratory Animal Care accredited
facility (AAALAC #000594). The NIH Office of Laboratory Animal Welfare assurance
number for the TNPRC is A3071-01. All clinical procedures, including administration of
anesthesia and analgesics, are carried out under the direction of a veterinarian. Blood was
collected while the animals were anesthetized with Tiletamine-zolazepam with
Burprenorphine given as an analgesic. All possible measures are taken to minimize
discomfort of all the animals used in this study. The University of Pennsylvania and
Tulane comply with NIH policy on animal welfare, the Animal Welfare Act, and all other
applicable federal, state and local laws.
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Results
Design and characterization of X4-ZFNs. To genetically disrupt the CXCR4
allele, we designed a pair of zinc-finger proteins (ZFPs) targeting the region of the cxcr4
gene that encodes residues Asp 187 to Val 196 in the second extracellular loop (ECL2) of
this seven-transmembrane domain receptor using methods previously described [29-32]
(Figure 3-1). The ECL2 was chosen because this region is less well conserved amongst
the CXC family of chemokine receptors, which should reduce the frequency with which
other CXC receptors might be targeted, and because ECL2 is important in supporting
interactions with the HIV-1 Env protein [37, 38]. Two ZFPs were designed to bind each
of two 12bp targets separated by 6bp in this region of CXCR4. Each ZFP was then fused
to a modified FokI cleavage domain, active preferentially as a dimer to reduce
nonspecific DNA cleavage, resulting in zinc-finger nucleases (ZFNs) [25]. Upon binding
of both X4-ZFNs, the FokI nuclease cleavage domains dimerize and then generate a
double strand break that can subsequently be repaired by error-prone NHEJ resulting in
mutations targeted to the cleavage site that can include missense mutations, deletions and
insertions (Figure 3-1).
Efficiency of CXCR4 allele disruption in human CD4+ T cells. To determine
the efficiency and specificity with which the cxcr4 genes could be disrupted in human T
cells, we produced a bicistronic Ad5/F35 vector to deliver the X4-ZFNs (AdX4-ZFNs).
The Ad5/F35 vector is a serotype 5 virus with the fiber protein from a serotype 35
adenovirus that utilizes CD46 for entry as opposed to the coxsackie and adenovirus
receptor (CAR), which is poorly expressed on human CD4+ T cells [39]. Primary human
CD4+ T cells were stimulated with anti-CD3/anti-CD28 coated magnetic beads and
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Error prone
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ACTGGAACACAACCACCCACAAGTCATTGGGGTAGAAGCGGTCACAGATATATC
ACTGGAACACAACCACCCACAAGTCATT GGTAGAAGCGGTCACAGATATATC
ACTGGAACACAACCACCCACAA
GTAGAAGCGGTCACAGATATATC
ACTGGAACACAACCACCCACAA
GAAGCGGTCACAGATATATC
ACTGGAACACAACCACCCACAA
GCGGTCACAGATATATC
ACTGGAACACAACCACCCACAA
GTCACAGATATATC
ACTGGAACACAACCACCCACA
GATATATC
ACTGGAACACAACCACCCACAAGTCATTGGTTGGGGTAGAAGCGGTCACAGATATATC

Reference
2bp deletion (1.4%)
9bp deletion (4.5%)
12bp deletion (2.6%)
15bp deletion (5.2%)
18bp deletion (11.2%)
25bp deletion (1.6%)
4bp insertion (2.5%)

Figure 3-1. Zinc finger nucleases (ZFNs) bind, cleave, and disrupt cxcr4. (A) A
CXCR4-specific ZFN pair was generated, comprised of two DNA-binding zinc finger
proteins (ZFPs) each fused with a FokI endonuclease monomer. Each ZFP was designed
to target 12 bp of cxcr4 sequence (in red), separated by 6 bp (in blue), conferring 24 bp of
total specificity. Upon binding of both ZFPs, the FokI domains can dimerize and cleave
the double stranded DNA. The subsequent double strand break is then repaired by error
prone non-homologous end-joining resulting in various targeted mutations and a nonfunctional protein product. (B) The most common mutations induced by the X4-ZFNs, as
detected by 454 deep sequencing, are indicated with their frequencies among all ZFNinduced lesions. In-frame deletions were preferentially generated with the most common
being an 18 bp deletion, referred to as CXCR4Δ18. Frequences were averaged across five
independent experiments in the absence of HIV infection.
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transduced 18 hours later with AdX4-ZFNs, AdR5-ZFNs which expresses previously
described CCR5-specific ZFNs [23], or an Ad5/F35 vector that expresses green
fluorescent protein (AdGFP). To identify optimal disruption conditions, multiplicities of
infection ranging from 100 to 1000 were employed. Cell growth was monitored every 48
hours post-stimulation for approximately two weeks, and the efficiency of CXCR4
disruption was assessed at day five post-transduction by both the Surveyor nuclease assay
and by deep-sequencing of the CXCR4 target site. As shown in Figure 3-2A, the
Ad5/F35 vectors had a slight dose-dependent impact on cell growth at higher
multiplicities of infection that was similar with the AdX4-ZFNs and AdGFP vectors.
Cxcr4 allelic disruption efficiencies as determined by either deep sequencing or
the Surveyor nuclease assay were comparable, and were approximately 10% at an MOI
of 100, 20% at an MOI of 300, 34% at an MOI of 600, and 38% at an MOI of 1000
(Figure 3-2B). For subsequent experiments we used an MOI of 600 as this provided nearmaximal disruption efficiency with limited impact on cell growth. Notably, this is also
the MOI being used in an adoptive therapy phase I clinical trial with R5-ZFNs.
Importantly, the level of cxcr4 disruption in cells from multiple donors was stable over
nearly four weeks in culture (Table 3-1), indicating that CXCR4-disrupted cells
continued to grow normally. Cell proliferation remained dependent on stimulation, and
transformation has not been observed after treatment with ZFNs (data not shown).
Mutations introduced by cleavage with X4-ZFNs. Deep sequencing of the
ZFNs target site 10 days after transduction made it possible to assess the mutations
introduced by NHEJ reactions following cleavage with X4-ZFNs. Of the nearly 50,000
modified cxcr4 alleles analyzed across five independent experiments, 81.1% (range 75.3-
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81.7%) contained pure deletions from 1-64 bp in size with the most common deletions
being 2, 9, 12, 15, 18, and 25 bp, while 13.5% (range 12.8-16.9%) of cxcr4 alleles
contained pure insertions ranging from 1 to 69 bp with more than 90% being 7 bp or less
(Figure 3-1B). The remaining 5.3% (range 4.3-7.4%) of disruption events contained
multiple insertions and deletions that may be due to more extensive DNA end-processing
or multiple cycles of ZFN-mediated cleavage and subsequent NHEJ. Surprisingly,
frameshift mutations occurred at a ratio of 0.90 in-frame per out-of- frame mutation as
opposed to the expected frequency of 0.50 (1 in-frame per 2 out-of-frame mutations;
Table 3-1). This unexpected bias likely resulted from microhomology-mediated joining
that produced in-frame deletions. To our knowledge, preferential in-frame repair has not
been reported or seen with other ZFNs [23, 40, 41].
To further characterize the consequences of disruption mediated by X4-ZFNs, we
analyzed an unusually common lesion, an in-frame 18 bp deletion (CXCR4Δ18) that
results in the deletion of DNA encoding amino acids R188 to D193 (Figure 3-1B). This
deletion comprised 11.2% (range 9.8 and 11.9%) of all cxcr4 disruptions across five
independent experiments with cells from five different donors. The resulting CXCR4Δ18
protein, containing a six-residue deletion in ECL2, could potentially be expressed at the
cell surface and support HIV infection. To examine this, we transiently expressed
CXCR4∆18 or wt CXCR4 as a control in 293T cells, which have low endogenous
CXCR4 expression. CXCR4 cell surface and intracellular expression was detected by
flow cytometry after co-staining with the N-terminal specific CXCR4 antibody 4G10 and
the extracellular loop (ECL) specific antibody 12G5 whose epitope includes the
CXCR4Δ18 deleted residues [42]. As expected, CXCR4 could be detected on the surface

104

1000
Cumulative live cell count
(x 10^6 cells)

A

Ad5/F35 X4-ZFN

Untransduced

100

MOI 100
MOI 300

10

MOI 600
MOI 1000

1

0

2

4
6
8
10
Days post stimulation

12

14

Cumulative live cell count
(x 10^6 cells)

1000
Ad5/F35 GFP

Untransduced

100

MOI 100
MOI 300

10

MOI 600
MOI 1000

1

0

2

4

6

8

10

12

14

Days post stimulation

B
% cxcr4 disruption (cel1)

40

Day 4
Day 8

30
20
10
0

0

100

300

600

1000

Ad5/F35 multiplicity of infection (MOI)

Figure 3-2. X4-ZFNs mediated disruption of cxcr4 in primary human CD4+ T cells.
(A) Primary human CD4+ T cells were stimulated and transduced with an Ad5/F35
vector expressing either the X4-ZFNs (top) or GFP (bottom) at MOIs from 100-1000.
Total live cells were counted at different times after stimulation, and compared to an
untransduced control. Data is from one of two independent experiments. (B) Cxcr4
disruption was determined four and eight days post treatment with the X4-ZFNs by the
surveyor nuclease assay (cel1).
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of control cells by both the N-terminal and ECL antibodies. However, CXCR4Δ18 was
not detected at the cell surface, though it was detected intracellularly by the N-terminal
antibody (Figure 3-3). In addition, cells expressing CXCR4Δ18 along with CD4 did not
support HIV-1 infection. These findings indicate that CXCR4Δ18, the most common inframe deletion resulting from the X4-ZFNs, does not readily traffic to the cell surface and
does not function as an HIV-1 coreceptor.
Specificity of cleavage by X4-ZFNs. Potential off-target genome modification
comprises the predominant safety concern with ZFNs. Although ultra-deep full genome
sequencing could best identify off-target effects, it is impractical and cost-prohibitive
with current technology. Instead, we took a more targeted approach that used an
experimentally derived binding site for each X4-ZFP to guide the identification of
potential off-target cleavage sites. We conducted in vitro selection, or SELEX (systemic
evolution of ligands by exponential enrichment) to determine the actual binding site
preference of each X4-ZFP (Figure 3-4) [43, 44]. A positional-weighted matrix was then
generated of the 12bp binding site and 1bp flanking region for each ZFP. A BLAST
search against the human genome was then used to determine the top 15 off-target
binding sites by allowing up to six mismatches per ZFP binding site, a 5 or 6 bp gap
between ZFPs, and formation of hetero or homodimers (Table 3-2) [23]. To assess low
frequency disruption events, we conducted 454 deep sequencing on all 15 sites in both
control CD4+ T cells and those treated with X4-ZFNs, yielding approximately 7,50026,000 reads per site in the ZFN-treated samples (Table 3-2). In a sample with 26.9% of
CXCR4 alleles disrupted, NHEJ events were detected at a frequency of 2.3% (170/7531
reads) in an extragenic region on chromosome 12 and 0.8% (84/10531) in 20,312 reads
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Figure 3-3. X4-ZFNs preferentially generate in-frame deletions resulting in the
absence of CXCR4 cell surface expression. The most common lesion induced by the
X4-ZFNs was an 18bp deletion, cxcr4Δ18, that results in deletion of the amino acid
sequence RFYPND from the second extracellular loop of CXCR4 (see Figure 3-1B). To
determine if CXCR4Δ18 was expressed on the cell surface, a mock, wild type cxcr4, or
cxcr4Δ18 plasmid was transiently transfected into 293T cells that have low endogenous
CXCR4 expression. Cells were then analyzed by flow cytometry after being stained
simultaneously with anti-CXCR4 clone 4G10, which recognizes the N-terminus, and
clone 12G5 whose epitope includes the second extracellular loop that is disrupted by the
X4-ZFNs. WtCXCR4 was detected equally by both antibodies on the cell surface (middle
panel, top row) and intracellularly (middle panel, lower row). However, CXCR4Δ18 was
not detected by the N-terminal antibody on the cell surface (right panel, top row), but was
detected when cells were permeabilized (right panel, bottom row) suggesting the 18bp
deletion prevents its expression on the cell surface.
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found in DEC1 (a putative tumor suppressor [46]) and the single mutation out of 21,139
reads found in an extragenic region of chromosome 11 could be due to PCR and
sequencing errors or to very low levels (< 0.02%) of ZFN-mediated cleavage events.
Overall, the X4-ZFNs are highly specific for cxcr4 with low frequency disruption clearly
seen at 2 of 15 putative off-target sites with the highest homology to the intended target.
X4-ZFNs confer in vitro protection to human CD4+ T cells from HIV
challenge. Disruption of both cxcr4 alleles should render human CD4+ T cells resistant
to X4- and perhaps some R5X4- viruses as well, while cells harboring a single disrupted
allele might express lower levels of CXCR4 and so be more resistant to virus entry. To
determine whether ZFN-mediated disruption of cxcr4 indeed protects CD4+ T cells from
an in vitro HIV challenge, human CD4+ T cells from three different ccr5 wild type
donors were stimulated and transduced with AdX4-ZFNs or an AdR5-ZFNs control. Four
days post-transduction, the cells were infected with three diverse HIV-1 strains: BK132
(primary X4 HIV), HxB2 (lab-adapted X4 HIV), or R3A (primary R5X4 HIV).
Approximately two weeks post-transduction the cells were restimulated with antiCD3/anti-CD28 beads, and cultures were maintained for an additional two weeks.
In the absence of HIV infection, there was no detectable growth difference
between the X4-ZFNs treated, R5-ZFNs treated, and non-transduced controls over the
course of the experiment. However, upon infection with the X4- or R5X4- HIV-1 strains,
X4-ZFNs treated cells maintained exponential growth compared to profound cell death
seen in the R5-ZFNs and untransduced controls. Despite the ability of R3A to utilize both
CCR5 and CXCR4 to infect cell lines, in human CD4+ T cells stimulated with antiCD3/anti-CD28 coated magnetic beads, CCR5 is downregulated causing transient
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Figure 3-4. Determination of putative off-target sites. The DNA binding preference of
the X4-ZFP left and X4-ZFP right was determined empirically by systemic evolution of
ligands by exponential enrichment (SELEX). Briefly, a random pool of oligonucleotides
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per side (faded). Nucleotides corresponding to the wild type cxcr4 sequence are shown
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resistance to R5 HIV [47]. Thus, R5X4 HIV strains are likely to function predominantly
as X4 HIV strains under these conditions [47]. The growth advantage conferred by
treatment with X4-ZFNs in the presence of HIV was magnified upon restimulation.
(Figure 3-5A). This likely resulted from increased cell activation, which increases the
ability of HIV to infect and replicate in CXCR4 positive cells.To determine whether the
growth advantage conferred by X4-ZFNs treatment in the presence of X4- and R5X4HIV resulted from a survival advantage of CXCR4 disrupted cells, we performed flow
cytometry at various time points post infection as well as deep sequencing of the X4ZFNs target site on HIV-infected and uninfected cultures. In the absence of HIV
infection, the cxcr4 disruption frequency remained stable over time in four independent
experiments testing four different ccr5 wild type donors as measured by deep sequencing.
A representative experiment is shown in Figure 3-5B and CXCR4 disruption data from
all experiments is shown in Tables 3-1 and 3-3. While CXCR4 gene disruption remained
stable over time at approximately 30%, CXCR4 gene disruption in HIV-infected cultures
increased to 87%, 91%, and 88% in the presence of BK132, HxB2, and R3A respectively
after 21 days of infection. FACS analysis showed that at day 19 post-HIV challenge, the
frequency of CXCR4 negative cells amongst all live mock HIV-infected CD4+
lymphocytes was 13.0% in untransduced cells, 14.1% in cells transduced with R5-ZFNs,
and 35.0% in cells transduced with X4-ZFNs compared to greater than 98%, 97%, and
99% of Bk132, HxB2, and R3A infected cultures transduced with the X4-ZFNs, (Figure
3-5C). We also found that after 19 days post-HIV infection, reduced but significant cell
growth was detectable in several of the HIV-infected control cultures,
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Figure 3-5. Treatment of human CD4+ T cells with X4-ZFNs confers protection to
HIV-1 challenge in vitro. (A) Human CD4+ T cells were treated with the X4-ZFNs or
R5-ZFNs expressed by Ad5/F35 vectors or were non-transduced (NTD). Four days later
cells were infected with a primary X4 HIV-1 (Bk132), lab-adapted X4 HIV-1 (HxB2),
primary R5X4 HIV-1 (R3A) or mock infected. The number of viable cells were measured
at various times after stimulation. Cells were re-stimulated on day 13 (arrows). (B) The
proportion of disrupted cxcr4 alleles was determined at the indicated times poststimulation by 454 deep sequencing. The frequency of cxcr4 disruption was relatively
constant in the mock-treated cells, but increased dramatically in the presence of HIV-1.
(C) FACS analysis using a CXCR4-specific monoclonal antibody was performed at 19
days post infection (24 days post-stimulation). Mock HIV-infected cultures are shown on
the left and HIV infected cultures on the right. Data shown is one of three independent
experiments.
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Table 3-3. Surveyor nuclease data after treatment with X4-ZFNs and challenge by HIV.
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untransduced and treated with R5-ZFNs. However, greater than 95% of these cells,
compared to approximately 10% of cells treated with X4-ZFNs, were CD3+CD4suggesting that the surviving cell population was protected from HIV infection by downregulating CD4 (Figure 3-6). Thus, CXCR4 disruption had no impact on cell viability,
but conferred a significant survival advantage in the presence of HIV strains that can use
CXCR4 to infect cells. Furthermore, in control cultures that were untransduced or treated
with R5-ZFNs, viral titers exponentially increased until extensive cell death began
approximately 8-10 days post infection. In contrast, in cultures treated with X4-ZFNs
viral titers steadily decreased after peak viremia while cell growth remained exponential
suggesting there was not significant viral production (data not shown).
Ccr5∆32 CD4+ T cells treated with X4-ZFNs are resistant to R5 and X4 HIV.
Given the ongoing adoptive therapy trial of CD4+ T cells treated with R5-ZFNs and the
anti-viral success of the recent ccr5∆32 bone marrow transplant in an HIV-infected, we
sought to determine if cxcr4 could be genetically disrupted simultaneously with ccr5.
Human CD4+ T cells from a ccr5∆32 homozygote were transduced with AdX4-ZFNs or
AdR5-ZFNs and subsequently infected with HIV-1 strains Bk132, HxB2, and R3A as
described above. Representative data from one of two independent experiments
conducted in cells from the same donor is shown in figure 3-7 and data from both
experiments is shown in Tables 3-1 and 3-3. As seen in ccr5 wild type CD4+ T cells,
exponential cell growth was preserved in cultures treated with X4-ZFNs compared to
control cultures that were untransduced or treated with R5-ZFNs (Figure 3-7A). In
addition, disruption frequency in cultures treated with X4-ZFNs as determined by deep
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Figure 3-6. Treatment with X4-ZFNs prevents CD4 downregulation by HIV-1. CD4
is profoundly downregulated on live CD3+ cells HIV-1 infected cultures that were NTD
or treated with R5-ZFNs but not X4-ZFNs. Thus, the limited cell growth remaining by 19
days post infection in NTD cultures and those treated with R5-ZFNs is due to HIV-1
induced CD4 downregulation, and thus the protective effect on cell growth for
CD3+CD4+ cells is underestimated by the growth curves in Figure 4A. Cells are from
same experiment as Figure 3-4 [6].
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sequencing remained remarkably stable between 32-33% from day 5 to day 26 posttransduction in the absence of HIV, which suggests that simultaneous disruption of ccr5
and cxcr4 does not adversely affect cell growth. However, in the presence of Bk132,
HxB2, and R3A, cxcr4 disruption increased after 21 days of HIV challenge to 89%, 83%,
and 90%, respectively (Figure 3-7B), and was associated with markedly diminished virus
replication (data not shown), again consistent with significant protection conferred by
cxcr4 disruption. Thus, treatment with X4-ZFNs of both wild-type and ccr5∆32 CD4+ T
cells confers stable cxcr4 disruption and a marked survival advantage in the presence of
R5X4-HIV and X4-HIV in vitro without any detectable effect on cell growth or viability
in the absence of HIV. This suggests that both ccr5 and cxcr4 can be genetically targeted
simultaneously for the treatment of HIV infection, while preserving the replicative
capacity of the CD4+ T cells.
X4-ZFNs confer partial protection in NSG humanized mouse model. As a
first step in evaluating the safety and efficacy of the X4-ZFNs in vivo, we employed a
NSG humanized mouse model. Briefly, human CD4+ T cells were stimulated with antiCD3/anti-CD28 beads and transduced with either AdX4-ZFNs or an AdR5-ZFNs control
at an MOI of 600. Cells were then expanded in vitro for ten days after which 107 CD4+ T
cells treated with X4-ZFNs (n=23) or R5-ZFNs (n=22) were injected intravenously into
each mouse. Engraftment was assessed by peripheral blood CD4+ T cell counts 27 days
post-injection. All 45 animals successfully engrafted; however, one animal that received
cells treated with the X4-ZFNs had a significantly higher but stable CD4+ T cell count
and was thus excluded as an outlier from the remainder of the study. On day 28 post-
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engraftment, mice were intravenously injected with 105 autologous CD4+ T cells that
were previously infected with the highly cytopathic X4 HIV-1 strain Bk132 or a mock
control. CD4 counts, viral load, and CXCR4 disruption were then monitored to determine
the effect of treatment with X4-ZFNs.
To determine if X4-ZFNs impacted cell growth or viability in the absence of HIV,
we first compared CD4 counts over time between the uninfected X4-ZFN and R5-ZFN
control mice. There was no significant difference in CD4 counts between the two groups
over the course of the 61 day experiment as determined by a generalized estimating
equation (GEE) method (p=.88) (Figure 3-8A). Next, we examined the frequency of
CXCR4 DNA disruption over time with the surveyor nuclease assay. At the time of
injection the percentage of cxcr4 alleles disrupted was 24.3%. This remained constant
inboth the blood (p=0.32) and spleen (p = .70) over the course of the experiment
suggesting that CXCR4 disruption did not significantly impact trafficking between these
two compartments (Figure 3-8B). Next, we characterized CXCR4 cell surface expression
over time by FACS. In the R5-ZFN control group, with intact cxcr4 genes, 88% of CD4+
T cells expressed CXCR4 protein at day 27 post engraftment, compared to 84% of cells
in the X4-ZFN mice (~24% cxcr4 gene disruption) as determined by a fluorescence
minus-one (FMO) control. This difference persisted over time in the absence of HIV-1
infection (p <0.001) (data not shown). Together the stable disruption of CXCR4 as
determined by both the surveyor nuclease assay and flow cytometry suggests that
CXCR4 disruption did not negatively impact cell viability or growth in humanized NSG
mice over a two-month period. As expected, xenogeneic graft versus host disease
(GVHD), assessed clinically by dermatitis and hair loss, was observed in mice receiving
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Figure 3-7. Treatment with X4-ZFNs is effective in ccr5Δ32 homozgyous human
CD4+ T cells. (A) Ccr5Δ32 CD4+ T cells were stimulated on day 0 and transduced on
day 1 with an Ad5/F35 vector expressing the X4-ZFNs, R5-ZFNs, or an untransduced
control. On day 5, cells were HIV-infected with a mock, primary X4 HIV-1 (Bk132),
lab-adapted X4 HIV-1 (HxB2), or a primary R5X4 HIV-1 (R3A). Live cells were
counted approximately every two days. Cells were restimulated on day 13 (arrows). (B)
Cxcr4 disruption frequency was assessed at various times by 454 deep sequencing.
Disruption remained stable in the absence of HIV-1 infection, but profoundly increased
in the presence of the three HIV-1 strains examined. Data shown is from one of two
representative experiments.
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cells treated with both R5-ZFNs and X4-ZFNs in the absence of HIV challenge. The
development of GVHD was equivalent between the two groups (data not shown),
suggesting that treatment with X4-ZFNs did not affect CD4+ T cell effector functionality.
In response to X4 HIV challenge with HIV-1 Bk132, CD4 counts decreased in
both X4-ZFN and R5-ZFN mice. However, this rate of decline was slower in the X4-ZFN
mice. The X4-ZFN group exhibited a mean 1.1 log CD4 count protection by day 14 post
infection (p=.05 for a parametric t-test). However, this protective effect waned over time
and there was no significant difference in CD4 counts by day 33 post infection (p=.88)
suggesting that treatment with X4-ZFNs conferred only transient protection (Figure 38A).
One mechanism that could account for this would be if mutations arose in the
viral Env protein to enable it to use CCR5. To explore this possibility, we bulk cloned
and sequenced the V3 loop of Env, the main determinant of coreceptor tropism [48], from
plasma isolated from three R5-ZFN mice and three X4-ZFN mice at the time of sacrifice.
We identified a single amino acid substitution (Y302N) present in Env isolated from X4ZFN mice but not R5-ZFN mice or the viral innoculum. Next, we cloned six distinct,
functional Envs from the X4-ZFN mice and three distinct, functional Envs from the viral
innoculum. As full length Bk132 Env would not pseudotype on an NL43 HIV core we
truncated the cytoplasmic tail of the Envs [49, 50], and conducted tropism testing on NP2
cell lines expressing CD4 with either CCR5 or CXCR4. Of the six functional Envs from
X4-ZFN mice, four contained the Y302N mutation. Interestingly, these four Envs were
able to utilize CCR5 and CXCR4 equivalently, similar to the R5X4-tropic control R3A.
All clones with the wild type Tyr302, including the Envs from the viral innoculum and
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two Envs from X4-ZFN mice utilized CXCR4 approximately 1000-fold more efficiently
than CCR5 and comparably to the X4-tropic control TYBE (Figure 3-8C). Thus, in an
NSG humanized mouse model of HIV infection, the cells treated with X4-ZFNs
engrafted, trafficked, and persisted comparably to control cells. In addition, treatment
with X4-ZFNs resulted in significant transient protection of CD4+ T cell counts in
response to X4-tropic HIV challenge, and HIV challenge provided cxcr4 disrupted cells
with a survival advantage as determined by increase of cxcr4 disruption in the presence
but not the absence of HIV. However, the extent of the protection conferred by the X4ZFNs was mitigated by evolution or outgrowth of preexisting R5X4-tropic HIV.
ZFN-mediated coreceptor disruption is feasible in rhesus macaque CD4+ T
cells. While humanized mouse models for HIV infection have utility, the model is
limited due to incomplete immune reconstitution, development of xenogeneic graft
versus host disease (GVHD), and the absence of normal T cell homeostasis. For these
reasons and others, the NSG model is suboptimal compared to non-human primate
models to further elucidate the safety and efficacy of treatment with X4-ZFNs and R5ZFNs. As a proof of concept for future clinical adoptive therapy studies, we attempted to
disrupt the ccr5 and cxcr4 genes with ZFNs in rhesus macaque CD4+ T cells. Briefly,
rhesus CD4+ T cells were isolated from whole blood, purified by magnetic bead negative
selection, and then stimulated with anti-CD3/anti-CD28 coated beads as previously
described [35, 36]. As the 24bp X4-ZFPs’ binding site is identical between rhesus and
humans, we were able to utilize the same ZFN pair. However, in order to target rhesus
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Figure 3-8. Treatment with X4-ZFNs confers partial protection to HIV-1 in
humanized mice in vivo. NSG mice were injected with human CD4+ T cells treated
with X4-ZFNs or R5-ZFNs. 28 days post injection, mice were infected with primary X4
HIV-1 (Bk132) or were mock-infected. (A) CD4+ T cell counts were measured every 710 days post infection. In the presence of Bk132, treatment with X4-ZFNs conferred
protection at 14 d.p.i (p=.05); however, this protection wanes by 34 d.p.i. (p=.88) (B)
Cxcr4 disruption frequency was assessed by the surveyor nuclease assay in both
peripheral blood (p<.001) and spleen (p<.001). At day 34 post infection, human CD4+ T
cells were purified by positive selection prior to analysis to reduce any bias from low
frequency contaminating human cells. Only samples with a detectable PCR signal are
shown. Disruption frequency did not deviate significantly from the cell innoculum in
either the blood or spleen. Data in (A) and (B) were analyzed by a general estimating
equation (GEE). (C) HIV-1 Env from X4-ZFN mouse plasma was sequenced revealing a
consensus Y302N mutation. To evaluate coreceptor tropism, a representative Env from
the X4-ZFN mice and the viral innoculum were pseudotyped and used to infect NP2 cell
lines expressing CD4 and either CCR5 or CXCR4. R5 HIV-1 (JRFL), R5X4 HIV-1
(R3A), and X4 HIV-1 (TYBE) controls are shown. Infectivity on NP2/CD4/CXCR4 cells
was divided by that on NP2/CD4/CCR5 cells to determine relative coreceptor use. Data is
an average of three independent experiments each done in triplicate. Error bars represent
standard error.
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CCR5, rhesus specific R5-ZFNs were developed. As for human cells, the ZFNs were
delivered with an Ad5/F35 vector and disruption was assessed by the surveyor nuclease
assay. Utilizing a range of MOIs of 600, 1000, and 2000 we observed mean ccr5 and
cxcr4 disruption levels of 19.6% and 14.0%, respectively (Figure 3-9), which suggests
that adoptive therapy of cells modified with ZFNs is feasible to model in rhesus
macaques.
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Figure 3-9. ZFNs can efficiently disrupt ccr5 and cxcr4 in rhesus macaque CD4+ T
cells. The X4-ZFN pair’s 24bp binding site is conserved between humans and rhesus
macaques. However, the human and rhesus R5-ZFNs have different binding sites; thus, a
novel CCR5-ZFN pair was generated targeting rhesus ccr5. The rhesus R5-ZFNs and
X4-ZFNs were delivered by Ad5/F35 vector at MOIs from 600-2000 into rhesus CD4+ T
cells. Disruption frequency was measured by the surveyor nuclease assay. Data shown is
an average of three independent experiments in cells from two different animals. Error
bars represent standard error.
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Discussion
The apparent eradication of HIV resulting from a ccr5Δ32 homozygous
allogeneic bone marrow transplant into an HIV-infected patient represents the first
reported “cure” of HIV [6]. While an important proof-of-principle, few individuals could
benefit from allogeneic ccr5Δ32 homozygous transplants due to toxicities of allogeneic
rejection and limitations of finding sufficient HLA-matched ccr5Δ32 homozygous
donors. However, coreceptor-specific ZFNs represent a novel therapeutic approach to
recapitulate this success via autologous transplantation of gene-modified hematopoietic
stem cells and mature CD4+ T cells. Ccr5 can be efficiently disrupted in both human
CD4+ T cells and hematopoietic stem cells, conferring protection to HIV challenge in
vitro and in humanized mice [23, 28]. In addition, transgenic autologous hematopoietic
stem cells can be successfully transplanted in HIV-infected individuals [18] and several
phase I adoptive transfer trials of CD4+ T cells treated with R5-ZFNs in HIV infected
individuals are currently underway. By design, this strategy addresses only viruses that
require CCR5 to infect cells. Our long-term goal, therefore, is to explore the potential to
genetically disrupt both ccr5 and cxcr4 for cell replacement therapies in HIV infected
individuals, and in the case of cxcr4 do so in a way that specifically targets CXCR4 on T
cells and not the many other cell types on which it is expressed. We hope this could lead
to long-term virologic control in the absence of continued ART, a critical goal of the HIV
field as discussed in chapter one.
Unlike for ccr5, there are no known humans with loss of function cxcr4 mutations
that would provide insight into the safety and viability of cxcr4 disruption in mature
CD4+ T cells. A concern associated with targeting CXCR4 is that it is broadly expressed,
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while CCR5 expression is largely limited to hematopoietic cells. CXCR4, along with its
natural ligand CXCL12, plays a critical role in normal B cell, cardiovascular, and
cerebellar development, though T lymphocytes appear to develop normally in cxcr4-/mice [51]. Thus, it is possible that the selective disruption of cxcr4 in mature post-thymic
CD4+ T cells may be tolerable. In addition to its role in development, the CXCR4CXCL12 axis is a potent CD4+ T cell chemoattractant, and the broad expression of both
proteins suggests that this axis may play a fundamental role in basal chemotaxis as
opposed to a response to inflammation [52]. Indeed, inhibiting CXCR4 function
systemically with the small molecule antagonist plerixafor results in the peripheral
mobilization of hematopoetic stem cells, thus mitigating the potential of such therapy for
long-term anti-retroviral therapy. However, plerixafor, which has not been reported to
have adverse immunologic consequences resulting from inhibiting CXCR4 function in
mature CD4+ T cells, provides proof of principle that inhibiting CXCR4 in mature CD4+
T cells may prove to be safe and viable [10, 53]. This suggests that this essential gene can
be targeted in a cell-type specific manner with CXCR4-specific ZFNs that limits the
toxicities of systemic disruption. While we have demonstrated that CXCR4 is not
essential for CD4+ T cell viability and function in vitro and in humanized mice in vivo,
the redundancy of lymphocyte chemokine receptors and their ligands makes predicting
the in vivo consequences of cxcr4 disruption in a normal host on CD4+ T cell function
and trafficking difficult. We conclude that a logical next step will be to study the
consequences of cxcr4 disruption in a non-human primate model of HIV infection, which
will simultaneously permit the assessment of the consequences of this approach on T cell
function and trafficking.
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A significant advantage of ZFN gene modification, compared to retrovirus based
approaches, is that only transient transgene expression is required to permanently
engineer an HIV resistant cell. As a result, adenovirus or other delivery mechanisms such
as RNA transfection can be employed that avoid toxicities that can be associated with
retroviral integration, such as cellular expansion or transformation. This “hit-and-run”
approach limits the requirement of chronic transgene expression and the potential
leakiness of other approaches including siRNA [21, 22], intrabodies [19], and ribozymes
[17]. However, like most gene transfer approaches a major concern with ZFN technology
is the potential for oncogenesis due to off-target effects. Efforts have been made to
reduce off-target effects by using modified Fok1 catalytic domains, which act as obligate
heterodimers, and future work will examine the effects of modulating the DNA binding
affinity of ZFN pairs on DNA specificity. While additional study is clearly needed, our
current studies have clearly identified off-target disruption in two of the top 15 putative
off-target sites: an extragenic site on chromosome 12 and in the metalloprotease
ADAMTS17, which is not expressed in CD4+ T cells. In addition, mature CD4+ T cells
appear to be resistant to malignant transformation [54], thus mitigating the potential
concerns of off-target disruption. Consistent with this, more than 200 people have safely
undergone adoptive transfer of genetically engineered lymphocytes with no reported
cases of therapy-induced oncogenesis [55]. Reasons for resistance to transformation of
mature lymphocytes are unclear, but may involve an unknown mechanism that ensures
the diversity of the TCR repertoire and thus limits clonal outgrowth [54]. In contrast, the
safety record of hematopoietic stem cell gene therapy is less clear, with a significant
frequency of gene-therapy induced oncogenesis or clonal outgrowth reported in several
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hematopoietic stem cell trials [56, 57]. However, given the continued production of
CD4+ T cells, a ZFN-based approach in CD4+ T cells may require intermittent lifelong
treatment.
One unexpected finding reported here is the predominance of in-frame mutations,
particularly in-frame deletions, resulting from ZFN mediated cleavage of cxcr4. This has
not been observed in other ZFN studies reported thus far. The deep-sequencing approach
we have taken makes it possible to comprehensively and accurately assess the types and
frequencies of mutations that result from ZFN cleavage followed by DNA repair. The
striking preponderance of in-frame deletions may have resulted from toxicities of
frameshift mutations shortly after treatment with X4-ZFNs leading to decreased survival
relative to in-frame mutants. However, this is unlikely given that the frequency of inframe mutations remained stable over nearly four weeks in culture, that there was no
significant increase in cell death between control cultures and those treated with X4ZFNs, and that the most common in-frame mutant was not expressed on the cell surface
and thus cannot maintain functionality. Rather, the preference for in-frame deletions is
likely due to preferential in-frame DNA repair. The deletion in the most common X4ZFN-induced lesion, cxcr4Δ18, is flanked by a GTCA microhomology domain at the 5’
and 3’ ends consistent with a repair mechanism of microhomology-mediated NHEJ [58].
Similar microhomology sites are present in other common ZFN-induced cxcr4 mutants
that we identified. Thus, it appears that the nucleotide sequence of the X4-ZFN binding
site directs a preference for an in-frame repair mechanism.
Our studies provide a fundamental demonstration that inactivation of cxcr4 by
treatment with X4-ZFNs rendered human CD4+ T cells resistant to infection by X4 virus
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strains, while CXCR4 inactivation in the context of a ccr5∆32 homozygous background
rendered cells resistant to infection by both R5 and R5X4 strains. Genetic ablation of
both CCR5 and CXCR4 will likely make CD4+ T cells entirely resistant to HIV-1. Dualdisruption of CCR5 and CXCR4 will be needed for maximal therapeutic benefit since
46% of treatment-experienced individuals harbor R5X4 strains of HIV compared to 4%
with only X4-HIV strains [59]. While virus strains have been identified that can infect
cells in the absence of CD4 (reviewed in [60]), none have been identified that can infect
cells in the absence of a suitable coreceptor. In addition, virus strains that can use
coreceptors other than CCR5 or CXCR4 to infect primary human cells are exceedingly
rare. However, targeting CXCR4 alone could provide a selective advantage to CCR5tropic virus strains. Suppression of CXCR4 by plerixafor in vitro can lead to the
emergence of CCR5-tropic virus strains [61], and highly active antiretroviral therapy can
sometimes result in enhanced prevalence of R5 relative to R5/X4 virus strains in infected
patients [62]. In the humanized mouse model under the conditions studied here, partial
loss of cxcr4 in human T cells due to treatment with X4-ZFNs provided selective
pressure for either the evolution or emergence of a pre-existing single amino acid
mutation in the V3 loop of the infecting X4 HIV-1 strain that enabled it to use CCR5 as
efficiently as CXCR4. Thus, just as either genetic or therapeutic suppression of CCR5
can provide an advantage to virus strains that use CXCR4, deletion of CXCR4 is
expected to provide an advantage to CCR5-tropic viruses. However, this could provide a
clinical benefit given the increased in vitro pathogenicity and correlation with
progression to AIDS of X4-tropic HIV.
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While humanized mouse models provided a logical first approach to examine in
vivo efficacy of CXCR4 disruption, this system does not make it possible to fully assess
the functional impact of CXCR4 loss on CD4+ T cell function. To study this in the most
rigorous way possible, we have explored the possibility of targeting CCR5 and CXCR4
in CD4+ T cells derived from rhesus macaques. Following re-design of the R5-ZFNs to
account for sequence differences between the human and macaque alleles, we found that
ZFNs could disrupt both alleles with reasonable efficiency in macaque CD4+ T cells. By
inactivating CXCR4 singly and in combination with CCR5, it will be possible to study
the effects of CXCR4 loss on T cell function as well as virus infection in a more relevant
animal model.
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Introduction
Acquired immunodeficiency syndrome (AIDS) is a devastating disease caused by
human immunodeficiency virus (HIV) mediated destruction of CD4+ T lymphocytes
[1,2]. Since its emergence over 25 years ago, HIV/AIDS has killed more than 25 million
people, and another 33 million are currently infected [3]. The profound effect of this
pandemic has led to tremendous research efforts to elucidate the mechanisms of the HIV
life cycle and identify susceptible targets for therapeutic intervention. Two critical goals
of the field are development of a vaccine to prevent new HIV-1 infections and effective
treatment enabling HIV-1 control in the absence of long-term anti-retroviral therapy,
termed here a “functional cure.”

Future directions
Understanding the HIV-1 transmission bottleneck. In chapter two, we examine
phenotypic properties of T/F Env glycoproteins in an effort to elucidate Env properties
that can be targeted in future vaccine and microbicide efforts. Probing for differences
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between clade B T/F and chronic Env glycoproteins, we employed a variety of
phenotypic assays in an attempt to reveal the cause of the genetic bottleneck during HIV1 transmission. We demonstrated that clade B T/F Env glycoproteins are more sensitive
to CD4 binding site MAbs b12 and VRC01 and that this differential neutralization
sensitivity correlates with differential binding of these MAbs. This suggests that there
are structural differences in the CD4 binding site between T/F and chronic Envs;
however, this did not manifest itself as a phenotypic difference in a variety of in vitro
functional assays assessing CCR5 utilization efficiency, entry inhibitor sensitivity, CD4+
T cell subset infection, DC trans-infection, or fusion kinetics. The significance of a more
exposed CD4 binding site in clade B T/F Envs remains to be determined. However, it is
possible that it may confer a subtle advantage during HIV-1 transmission that is
magnified over multiple rounds of replication, and that the single-round infection assays
we employed may be insufficient to detect such a modest difference.
There are several areas of future direction for the study of T/F viruses. First,
while Env is a likely viral candidate responsible for the transmission bottleneck, a more
rigorous approach would utilize full-length infectious molecular HIV-1 clones. This may
reveal roles of other key HIV genes as well as interactions between these gene products
and Env that may play a role in transmission. Second, our study has highlighted that the
selection of well-matched chronic control viruses is critical. For instance, compared to
the T/F Envs our test panel of chronic Envs was significantly more resistant to VRC01;
however, our validation panel of chronic Envs was similar to the T/F Envs. The test panel
was geographically matched to the T/F Envs while the validation panel was from a
geographically distinct region; thus, geographical or other factors may have a significant
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confounding effect. We propose that future studies should employ T/F and chronic
control viruses from serodiscordant couples or less optimally, longitudinal samples from
infected individuals. Third, transmission of clade B HIV-1 represents a fraction of new
HIV-1 infections [4]. As it is possible that the cause of the transmission bottleneck may
be different among HIV-1 clades, future studies should expand our work to examine
other clades, most notably clade C, the predominant subtype globally [4]. Fourth, while
the in vitro assays used in chapter two are well validated and have previously revealed
subtle differences between different Envs [5,6,7,8], it is possible that they are not
sufficiently replicating events impacting the genetic bottleneck in vivo. Thus, more
sensitive and/or sophisticated assays involving human tissue explants and replication
competent virus should be utilized, which may reveal more subtle functional differences
between T/F and chronic HIV-1. In summary, future studies should use infectious
molecular T/F and chronic HIV-1 clones from serodiscordant couples and examine
functionality in tissue explants or other replication competent in vitro assays.
Towards a functional cure of HIV-1: the role of ZFNs. The recent report of the
‘Berlin patient’ suggests that heterologous transplants of HIV-resistant hematopoetic
cells may be of clinical benefit [9,10]. However, this is not feasible on a large scale due
to the morbidity and mortality of heterologous transplants and the dearth of ccr5Δ32
donors. Coreceptor specific ZFNs may overcome this limitation by allowing gene
modification of one’s own cells for autologous transplant. Previously, CCR5-ZFNs have
been developed [11] and several clinical trials are currently ongoing to assess preliminary
safety and efficacy (clinicaltrials.gov identifiers NCT00842634, NCT01252641,
NCT01044654). While CCR5-based therapies represent a viable approach to control
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HIV-1, efficacy of such therapy may be limited due to evolution or outgrowth of preexisting X4 HIV [12,13,14,15].
In chapter three, we generated X4-ZFNs to genetically engineer X4 HIV-resistant
CD4+ T cells for autologous transplant in HIV-infected individuals. The X4-ZFNs
efficiently and stably disrupt cxcr4, have no adverse affect on cell growth or stability, and
provide protection to X4 HIV challenge in vitro and in a humanized mouse model.
However, several areas of future work are needed prior to using X4-ZFNs in humans for
the treatment of HIV-1 infection.
First, while infection with X4 HIV occurs in about 50% of late stage individuals
in the developed world [16,17], infection with a pure population of X4 HIV is relatively
uncommon since most individuals also harbor either R5 or R5X4 HIV [18]. Thus,
genetic disruption of both ccr5 and cxcr4 may be needed for maximal therapeutic benefit.
By using X4-ZFNs in ccr5Δ32 cells, we have shown that genetic disruption of both
coreceptors is viable in vitro, but future work is needed to optimize delivery of both R5and X4-ZFNs to disrupt both copies of both genes in the same cell. One concern with
simultaneous delivery of two ZFN pairs is increased off-target activity resulting from
trans-heterodimerization of the two different ZFN pairs. Recent modifications in the
Fok1 catalytic domains have been made creating ZFN pairs that act as obligate
heterodimers [19]. This should be applied to the R5- and X4-ZFNs to minimize off-target
activity resulting from simultaneous delivery of two ZFN pairs.
Second, while cxcr4 disruption does not impact T cell development or function in
mice [20,21] and seems well tolerated in human CD4+ T cells in vitro, further work is
needed to assess the safety and viability of cxcr4 disruption in vivo because unlike for
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ccr5 there are no known humans with cxcr4 loss of function mutations due to CXCR4’s
critical role in embryonic development [21]. Thus, adoptive therapy studies of X4-ZFN
modified CD4+ T cells should be conducted in rhesus macaques to evaluate the effect of
cxcr4 disruption on cell viability, trafficking, and function in vivo. If cxcr4 disruption is
well tolerated in vivo then an X4-SHIV challenge should be performed to assess efficacy
prior to using X4-ZFNs in humans. Unlike for the R5-ZFNs, the 24bp binding site of the
X4-ZFNs is identical between rhesus macaques and humans which would allow the use
of the same ZFN pair and increase the validity of extrapolating safety, off-target, and
efficacy data from macaques to humans.
It is unlikely that any gene therapy approach will achieve 100% gene modification
as seen in the ‘Berlin patient,’ and thus important questions moving forward are can we
increase ccr5 and cxcr4 disruption efficacy and what frequency of gene disruption is
necessary for clinical benefit. Gene disruption efficiency may be increased through a
combination of alternate ZFN delivery methods, hypothermic shock [22], optimization of
cell stimulation, and administration of small molecules that alter chromatin structure,
ZFN activity, or host DNA repair pathways. The minimal frequency of coreceptor
disruption necessary for therapeutic benefit should be evaluated in humanized mice and
rhesus macaques.
Next, in addition to receiving ccr5Δ32 cells, total body irradiation, graft versus
host disease, chemotherapy, and other immunosuppressants may have played a role in
“curing” the ‘Berlin patient’ [10,23]. While we feel coreceptor ablation is critical, it may
not be sufficient to recapitulate the ‘Berlin patient,’ and thus the role of
immunosuppressants such as anti-thymocyte globulin and cyclophosphamide should be
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explored to reduce the latent HIV-1 reservoir and improve engraftment of gene-modified
CD4+ T cells and HSCs. In summary, genome editing of the HIV-1 coreceptors with
ZFNs represent a novel therapeutic strategy that may lead to long-term control of HIV-1
in the absence of ART.
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